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ABSTRACT 
 
 
 Despite years of research, a significant gap remains between the cancer burden 
requiring treatment and the mechanisms currently available in clinical settings.  Although 
great strides have been made in improving radiation therapy, the issue of non-specific 
irradiation of healthy tissue still persists.  One of the most promising modalities currently 
being explored involves using contrast material to enhance the radiation sensitivity of a 
tumor.  Such treatment aims to create a gradient in the photon attenuation coefficients of 
the tumor compared to those of the surrounding healthy tissue.  The goal of generating 
such a variation is to dramatically increase the amount of effective dose received by the 
tumor without increasing the amount received by the surrounding healthy tissue.  Several 
contrast materials have been explored for this application with iodine and gadolinium 
receiving generating significant interest.  Following the promising results achieved by 
utilizing gold nanospheres in murine models, interest in gold has correspondingly 
increased. 
 
This work examines several variables as they might pertain to the effectiveness of 
using gold as a radiation-sensitizing agent.  Physical considerations involving the incident 
photon energy, geometric considerations involving the depth of the tumor, and 
concentration considerations involving the amount and distribution of gold around the 
tumor site have all been explored.  Results were tabulated by comparing the amount of 
energy deposited per unit mass in the gold-bearing tumor volume compared to the 
surrounding healthy tissue and this ratio was termed the effective dose enhancement 
factor (DEF).  Using a gold concentration of 7 mg per kg of tumor resulted in DEF values 
ranging from 62%, when a 100 keV photon beam was modeled, to less than 1%, when 
applying a 2 MeV photon beam.  Varying the depth of tumor had less effect than 
expected as increasing the depth from 5 cm to 15 cm only increased the effective dose 
enhancement from 16% to 19% when using a 250 keV photon beam.  Varying the in situ 
gold concentration had the most significant effect as expected and DEF values increased 
by a factor of four from 18% to 76% as concentration was increased from 7 mg/kg to 40 
mg/kg.  The results obtained from using a more detailed geometric and concentration 
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model and considering realistic distribution patterns may be of use when designing future 
in vivo studies.  The results of the distribution and penetration models may be used to 
predict the effective dose profiles for tumor masses that are resistant to nanoparticle 
influx.   
 
Monte Carlo simulations were developed using Cartesian geometry and all 
material specifications and gold concentration data were obtained from the literature.  
Tissue and tumor were treated as homogeneous mixtures of their component elements, 
and gold nanoparticles were modeled as homogenous distributions where specified.  Flux 
and energy deposition calculations were performed using Monte Carlo N-Particle Code 
version 5.1.51. 
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Chapter I 
Introduction 
 
 
 According to the World Health Organization, cancer is one of the leading causes 
of death in the world, with about 8 million deaths (13% of all deaths) attributed to the 
condition in 2007.  Rising from 7.4 million deaths in 2004, this number is projected to 
rise to an estimated 12 million deaths within the next two decades [1].  Although it is a 
very broad term applicable to a group of diseases affecting any part of the body, cancer 
can essentially be described as a rapidly proliferating mass of cells growing without 
bounds or control.  Arising from chromosomal damage or genetic mutations in a single 
cell or small group of cells, cancer can progress from a lesion to a benign growth to a 
malignant tumor.  This progression is dependent on the severity of the original mutation, 
continued exposure to carcinogenic factors, and treatment efficacy.  Although the types 
and frequencies of cancer differ widely around the world, the most commonly hit areas of 
the body include the lungs, stomach, liver, colon, prostate gland and breasts.   
 
A comprehensive study of risk factors for cancer determined that avoiding key 
risk factors could prevent the occurrence of about 30% of all cancer [2].  Although 
several of the factors listed such as tobacco and alcohol use, physical inactivity, and 
pollution may be avoidable, assuming that all carcinogenic factors – physical, chemical, 
and biological – can be eliminated is not realistic.  In addition, some studies suggest 
inheritable genetic factors in the occurrence and development of cancer.  Consequently, 
even in ideally achievable environmental circumstances, a significant cancer burden 
remains to be treated.   
 
Several treatments have been tried over the years with varying levels of success 
including surgery, chemotherapy and radiotherapy.  The goal of each of these treatments 
is to remove or kill the tumor cells while minimizing inadvertent damage to the 
surrounding healthy cells.  To that end, the calculations and results described in this work 
should prove useful in improving tumor-specific radiation doses without increasing the 
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dose to the surrounding tissue.  The goal of this work is to quantitatively describe the 
benefits and possible limitations of using gold as a radio-sensitizing agent in all 
radiotherapy applications.  Significant work has been done to illustrate the benefits of 
using gold with implanted radiation sources due to the improved dose enhancement seen 
at lower photon energies.  However, this work will demonstrate that dose enhancement of 
several tens of percent can be seen when gold is used as a sensitizing agent with photon 
energies typical of external beam therapy.  In order to better understand the properties of 
each of the treatment modalities and the specifics that might affect the use of gold in 
treatment, the three main treatment options currently used to treat cancers are described 
below.  
 
 
1.1 Current treatment options 
 
The success of treatment modalities depends on the type, size and location of the 
tumors, and time lapse between onset and diagnosis of the condition.  Regardless of 
overall efficacy, however, each of these treatments has several associated side effects.  
Surgery is dependent on, and often drastically limited by, the level of access to the tumor 
location.  Deep tissue tumors may require significantly invasive surgery while those in 
difficult to reach locations like the brain may be completely inoperable.   
Chemotherapeutic agents, though minimally invasive, are extremely toxic and non-
specific targeting of the drugs can cause severe cell damage to normal cells.  
Radiotherapy has similar problems with non-specificity.  Although effective deep tissue 
treatments can be developed through creative use of external beam geometries, surface 
tissue can be subject to unwanted and widespread radiation in the process.  Meanwhile, 
implanted seed brachytherapy treatments can require invasive surgery while radioisotope 
therapy can result in radiation deposition along the entire route from injection to tumor 
localization.  Similarly, immunotherapy and hormone therapy can have undesirable side 
effects.  While the specifics of each of these therapy regimens are not the focus of the 
work presented here, it is beneficial to understand the general principles underlying each 
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modality as gold-mediated radiation therapy may be combined to create synergistic 
treatment regimens based on tumor conditions. 
 
1.1.1 Surgery 
 
Although limited by tumor location, surgery is the only way to specifically ensure 
the removal of cancerous cells without killing healthy cells.  Excision surgery is 
significantly invasive, however, and is only effective if the tumor is confined to one area 
of the body, i.e. has not metastasized.  Metastatic tumors that have impacted multiple 
organs are often too widespread for excision to be an efficient treatment strategy.  In 
addition, cancers that do not produce localized tumors, such as leukemia, are not treatable 
by surgery as there are no specific masses to remove. 
 
Other modes of therapy are often combined with surgery in an effort to make the 
entire treatment regimen more effective.  Neoadjuvant therapy is given prior to surgery in 
an attempt to reduce tumor size and ensure easier tumor removal.  This may include a 
combination of chemotherapeutic agents and hormone therapies.  Adjuvant therapy is 
given following surgery in an attempt to reduce the chance of relapse and recurrence.  An 
example of such a synergistic treatment is the use of the Gliadel wafer for glioblastomas 
multiforme.  The wafer, when placed directly onto the tumor site after excision surgery, 
delivers drugs through a controlled release mechanism [3].  The combination of tumor 
removal and controlled release chemotherapy has been documented to significantly 
reduce the spread of the tumor.  Gold nanoparticle therapy may prove to be another tool 
for adjuvant or neoadjuvant therapy regimens. 
 
1.1.2 Chemotherapy 
 
Anti-oncogenic drugs have been the subject of intense research for several 
decades.  Numerous drugs have undergone clinical trials and are available on the market.  
These drugs function by disrupting cellular function during key steps of the cell cycle in 
an effort to minimize or eliminate tumor proliferation.  Anthracylines, such as 
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Doxorubicin, act through DNA-intercalation interactions that disrupt nucleic acid 
structures and inhibit the DNA replication functions of cancerous cells [4].  Taxanes, 
such as Docetaxel, act by stopping key steps in the mitotic process, thereby eliminating 
cell replication [5].  Effective as they are, these drugs do not distinguish between healthy 
cells and tumor cells.  As a result, the delivery system for these drugs must be designed in 
such a way to take advantage of localized differences at tumor sites. 
 
In an effort to improve treatment efficacies, there has been considerable work 
done in the areas of nanobiology and nanotechnology and their applications to medicine.  
The ultimate goal is to develop novel treatment mechanisms that are triggered by tumor-
specific stimuli such that cancerous cells are specifically and preferentially targeted.  
Tumors are subject to Enhanced Permeation and Retention (EPR) effects and localized 
pH environments that can be used to uniquely identify them for treatment purposes.  
These properties, described in a later section, allow for the development of drug delivery 
systems that do not release the toxic agents before reaching the target sites.  Other clinical 
studies have tried to take advantage of the highly vascular nature of rapidly proliferating 
tumors by using anti-angiogenesis treatments [6].  The targeting strategies used for 
chemotherapeutic agents can be easily modified for use with gold nanoparticle agents in 
clinical applications and the simulations described in this work assume gold nanoparticle 
transport using EPR effects. 
 
1.1.3 Radiation therapy 
 
 In general, radiation therapy can be broken into three main categories: external 
beam therapy (teletherapy), implanted internal radiotherapy (brachytherapy), and Radio-
Isotope Therapy (RIT).  Additionally, there are two distinct types of radiotherapy 
procedures: photon therapy and particle therapy.  Each radiotherapy procedure is 
designed to eliminate tumor masses by causing DNA damage in the nucleus of the tumor 
cells.  Cells have inherent DNA repair mechanisms, but double-stranded breaks are 
generally irreparable.  Photon therapy induces DNA damage indirectly by creating radical 
species in the tumor blood supply that then cause the DNA damage.  Particle therapy, 
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generally involving neutrons, protons, or other charged particles, can deposit enough 
energy at the tumor site to directly cause the double-stranded DNA damage. 
 
 Each of the three types of radiation therapy techniques is ultimately designed to 
destroy tumor cells while protecting healthy cells.  The goal of using a selectively 
sensitizing agent is to enhance the ratio of dose given to the target cells compared with 
the healthy cells.  Gold has been proposed as a potent radio-sensitizing agent in this 
regard due to its high-Z nature and general biocompatibility.  Described below are the 
three main types of radiation therapy with comments on how the use of gold might 
improve treatment efficiency. 
 
Teletherapy: External beam therapy is the most common form of radiation therapy in 
current medical use.  Table 1-1 describes medically relevant x-rays based on peak tube 
voltage.   
Table 1-1: Classification of x-rays based on beam voltage 
Terminology Beam voltage Max. photon energy 
Diagnostic x-rays 20 kV – 150 kV 150 keV 
Orthovoltage x-rays 200 kV – 500 kV 500 keV 
Megavoltage x-rays 1 MV – 25 MV 25 MeV 
 
The prevalence of x-ray machines in use for imaging purposes makes an orthovoltage x-
ray source easily available in most hospitals – an orthovoltage x-ray source differs from a 
diagnostic x-ray source only in the applied terminal voltage.  Megavoltage x-rays are 
normally generated using a commercially available linear accelerator (linac) and are used 
for most teletherapy procedures commonly in use today.  X-rays are produced over an 
energy spectrum with the maximum beam energy dependent on the peak beam voltage.  
These spectra must be collimated using a variety of filters to obtain the energy and shape 
of the beam required.  Cobalt units producing dichromatic beams of 1.17 MeV and 1.33 
MeV can also be used to generate the necessary radiation beams.  Here the discrete 
energy nature of the beam makes up for the fact that higher or lower energy beams cannot 
be produced. 
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  Conventional beam therapy involves the use of two-dimensional beams targeted 
at a tumor site.  The use of multiple beams from different directions allows physicians to 
tune the absorbed dose at the tumor site.  While the most well established teletherapy 
procedure, conventional beam doses are limited by the sensitivity of adjacent healthy 
tissue that can receive substantial radiation doses during some high-dose treatments.  A 
combination of high resolution imaging techniques (such as Magnetic Resonance 
Imaging and Computed Tomography) along with beam collimation has resulted in the use 
of conformal teletherapy.  Here, the tumor volume and the corresponding radiation dose 
volume can be well defined and the dose delivered to nearby healthy tissue is reduced.  
Newer techniques are being developed to use beam modulation in real-time to help 
optimize the dose being delivered to the tumor site.  Examples of these techniques 
include Intensity-Modulated Radiation Therapy (IMRT), which uses precise tuning of 
“beamlet” energy to improve the shape of the delivered dose, and Image-Guided 
Radiation Therapy (IGRT), which uses real-time imaging techniques to visualize and 
tune the delivered dose. 
 
Teletherapy involving charged particles is a field of growing interest but is still 
significantly less developed than photon therapy.  Electrons have a maximum dose 
deposition depth of less than 5 cm, which makes an electron beam well suited for treating 
surface lesions but not very useful for deep tissue tumors.  Protons and heavier ion beams 
deposit energy near the end of the beam path as described by the Bragg peak shown in 
Fig. 1-1a.  This peaking characteristic is useful for treating tumors at greater depths since 
the energy of the particles can be tuned to ensure maximum energy deposition precisely 
at the tumor site.  However, this technique becomes problematic for tumors with a 
significant volume.  Ion beams of different energies must be used to target the entire 
tumor volume and the summation of the energy deposition curves results in the Spread-
Out Bragg Peak (SOBP) shown on Fig. 1-1b [7].  Thus, while the entire tumor volume 
can be irradiated, tissues shallower than the tumor can receive significant amounts of 
radiation dose.  By comparison, the energy deposited by a photon beam decays 
exponentially after the peak value, and a significantly smaller fraction of energy is 
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deposited at depths shallower than the target volume.  Thus, the beam energy can be 
tuned to ensure maximum dose at the required depth while minimizing collateral dose. 
 
 
 
 
Figure 1-1: Relative dose deposition as a function of depth. Three different radiation types are 
shown.  a. Exponential decay for photon beams compared to the Bragg peak characteristic for 
proton beam.  b. Fractionated proton doses targeting a tumor volume can result in significant 
accumulation of effective dose at shallow depths. [Adapted from 7] 
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Brachytherapy: Internal radiotherapy involves the placement of a radioisotope inside or 
near the area needing treatment.  The benefits of an implanted source stem from the fact 
that the radiation is impingent on a localized area and the dose to the surrounding healthy 
tissue is minimized.  Since beam geometries and penetration depth are not influencing 
factors, the dose rate and source strength can be tailored specifically to the target tumor.  
Nevertheless, treatment efficacy is dependent upon the location of the tumor, as the 
placement of the source must avoid unaffected vital organs.  As a consequence of the 
localized doses, brachytherapy has far fewer radio-toxicological side effects and has been 
successfully used to treat a variety of cancers including cervical, prostate, breast and skin 
cancers.  The following isotopes have been used as radiation sources for brachytherapy: 
  
Table 1-2: Commonly used sources for brachytherapy applications 
Isotope Principal -ray Energy 
Cesium
137
 662 keV 
Cobalt
60
 1.16 MeV, 1.33 MeV 
Iridium
192
 380 keV (mean) 
Iodine
125
 27.4 keV, 31.4 keV, 35.5 keV 
Palladium
103
 21 keV 
Ruthenium
106
 3.54 MeV 
 
Radioisotopes with shorter half-lives can be used in the design of quasi-
permanent brachytherapy treatments in which the radioactive seeds can be placed at the 
tumor site permanently with treatment duration limited by the radioactive decay of the 
isotope.  Longer-lived radioisotopes can be used for temporary brachytherapy treatments 
in which the seeds are placed at tumor sites for up to 24 hours and then removed.  
Additionally, brachytherapy regimens can be designed to have variable dose rates 
depending on the source isotope used.  Low-Dose Rate (LDR) brachytherapy involves 
radioisotopes with an absorbed dose rate up to 2 Gy/hr.  By comparison, High-Dose Rate 
brachytherapy (HDR) can make use of sources with absorbed dose rates exceeding 12 
Gy/hr.  Tumor location and cancer type will determine both the duration of treatment and 
the type of source that is used for treatment. 
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Radio-Isotope Therapy:  RIT involves the injection or ingestion of radioactive isotopes 
such that they preferentially accumulate at tumor sites.  As a result, RIT may be 
considered a specialized form of chemotherapy as well.  This therapy is commonly used 
to treat thyroid cancers and cancers of the neuroendocrine system – namely, cancers that 
do not respond well to surgery or have a high risk of recurrence after surgery.  
Additionally, RIT may be used to treat conditions that only affect specific portions of an 
organ such as bone metastases of certain cancers.  Commonly used isotopes include I
131
 
(has a thousand-fold accumulation preference for the thyroid compared to other organs), 
Y
90
 (has an affinity for peptide receptors to treat neuroendocrine tumors), and Sr
89
 (has an 
affinity for metastasis-affected bone over healthy bone).  While RIT has been shown to 
successfully treat certain cancers, there is a danger of whole-body radiation delivery by 
damage to epithelial surfaces as the radioisotope travels through the body before reaching 
the targeted area.  Affected areas may include the skin, oral, pharyngeal, and bowel 
mucosa depending on the targeted area. 
 
 
1.2 Tumor properties 
 
 In order to determine how large of an improvement can be expected from the 
addition of gold to existing treatment options, it is important to understand the specific 
characteristics of tumors that differentiate them from healthy cells.  Ideally, these unique 
attributes can be used to modify the radiation response of the affected area to ensure that 
only the tumor cells receive elevated doses of radiation while minimizing the dose to the 
surrounding tissue.  There are three main properties of tumors that can affect the 
localized responses to radiation – leaky blood vessels, localized acidity, and hypoxia.  
Two of these properties, leaky vessels and acidity, are routinely used to develop targeting 
mechanisms for existing chemotherapy regimens.  It is the third property, hypoxia, that 
proves the most problematic when determining radiation dose to tumors as described 
below.  It is assumed that the advances in nanomedicine regarding effective drug delivery 
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systems using these properties can be applied to the transport of gold nanoparticles to 
tumor sites. 
 
1.2.1 Enhanced Permeation and Retention (EPR) 
 
The majority of tumors are composed of rapidly proliferating cells with little or 
no cell cycle regulation.  This growth requires a significant increase in blood supply to 
the rapidly dividing cells and as a result, tumor cells over-express certain growth factors, 
such as Vascular Endothelial Growth Factor (VEGF) and Tumor Necrotic Factor (TNF), 
recruit additional blood vessels to the tumor site.  The rapid, irregular, and unregulated 
development of blood vessels supplying the growing tumor cells results in a lack of 
proper alignment of the endothelial cells in the vessels.  This, in turn, results in the 
presence of wide gaps in the vessels that give rise to the characteristic leaky vessel 
phenomenon associated with tumor masses.  This leaky architecture coupled with the 
lack of a proper lymphatic drainage system means that any particle circulating in the 
blood supply that is smaller than the gaps will escape the leaky vessels at the tumor site 
as seen in Fig. 1-2 [8].   
Figure 1-2: Nanoparticle extravasation through EPR effects.  Leaky vessels proximal to 
tumor sites allow nanoparticles to pass through [8] 
1: Nanoparticle is stable in circulation. 
2: Gaps in the blood vessel near the tumor allow nanoparticle escape 
3-4: After extravasation, nanoparticles accumulate at tumor site since they are 
too large to re-enter the vessel through the normal endothelial gap junctions. 
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Since the unregulated angiogenesis means there is no accompanying increase in 
lymphatic drainage at the tumor site, once a particle escapes a vessel at the tumor site, it 
will remain there.  As a result, particles designed to be stable enough to remain in 
circulation for an extended period of time will eventually accumulate at the tumor site 
through this Enhanced Permeation and Retention (EPR) effect [9].  This effect has been 
successfully used in various different drug delivery systems and is assumed to be the 
primary targeting mechanism for the purposes of this study.  Free circulating gold 
nanoparticles should accumulate at tumor sites resulting in a concentration of gold at the 
tumor site while the remainder gets cleared from the body through the renal system.  
Fenestrations in the leaky vessels can be as large as several hundred nanometers, and 
studies have shown that particles up to 100 nm can be used to passively target tumors 
[10, 11].   Additionally, a study by Chithrani et al. showed that cellular uptake of gold 
nanoparticles is most efficient using 50 nm particles while significant cellular uptake was 
seen for particles up to 72 nm in size [12].  
 
1.2.2 Localized acidity 
 
Another property that differentiates tumor cells from healthy tissue is localized 
acidity compared to physiological pH.  Since the extracellular pH environment at tumor 
sites is slightly acidic (median pH of 6.5 compared to pH 7.4), a triggered release 
mechanism can be developed to ensure targeted drug delivery and reduce any associated 
non-specific toxicities [13].  The reasons for this localized acidity have been theorized in 
published literature but no conclusive theory has been established as the root cause.  
Nevertheless, the unique physical environment exists, has been used in treatment 
applications, and may potentially be used for gold transport in future developments. 
 
1.2.3 Hypoxia 
 
 The tumor property that most significantly impacts the response to a radiation 
dose is the hypoxia that develops at the center of tumor masses.  As mentioned above, 
tumor cells proliferate at an accelerated rate and rapidly recruit the formation of blood 
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vessels to supply the growing mass with nutrients.  However, it is important to note that 
these blood vessels are only recruited at the surface of the tumor.  The rapid growth 
actually results in the blood supply being choked off from the center of tumor mass 
resulting in a locally hypoxic environment compared to the periphery of the tumor and 
compared to normal cell structures. 
 
 The reason this significantly impacts radiation response is that oxygen is a fairly 
potent radiosensitizer.  The radical ions created by photon beams, that subsequently cause 
DNA damage, are primarily comprised of oxygen species.  As a result, a decrease in the 
amount of oxygen present at the tumor site decreases the effectiveness of the photon 
beams in destroying the targeted tumor cells.  Higher dose delivery becomes necessary to 
surmount these hypoxia-induced effects.  Several drugs have been used to combat this 
reduced radiation efficacy – they work by introducing pharmaceutical agents that mimic 
oxygen‟s ability to act as a radiosensitizer.  One of the goals of this work is to show that 
implanted or accumulated gold at tumor sites can act as an extremely efficient 
radiosensitive agent.  Corroborating work done in the past showing the effectiveness of 
using gold-modulated radiation therapy, the work presented here should provide a 
foundation for the various physiological dependences of using gold. 
 
A final note on tumor-specific properties: Gold delivery and drug delivery 
mechanisms in general have not been addressed in the scope of this work.  Nevertheless, 
as maximal nanoparticle uptake in cells occurs at sizes smaller than the upper limit of the 
EPR window at tumor sites, it is suggested that the size of the particles can be tuned to 
optimize the therapeutic and diagnostic efficiencies without adversely affecting delivery 
efficiency.  As a result, all simulations described in this work assume particle sizes 
previously reported in both in vitro and in vivo murine studies, and do not address any 
site-specific delivery concerns.  Those concerns must be and have been addressed in 
separate studies as discussed. 
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1.3 Radiation interactions with matter 
 
 Before discussing the mechanisms for localized dose enhancement at tumor sites, 
it is important to discuss the different processes through which the incident radiation 
interacts with the targeted tissue.  Understanding the mechanisms in question can lead to 
a much better understanding of the relevant variables that need to be controlled in order 
to create a more effective treatment regimen.   
 
Brachytherapy sources emit gamma rays in the tens of keV range, while 
teletherapy generally uses megavoltage x-rays in the MeV energy range.  As a result, 
interaction cross-sections must be investigated over an energy range of 10 keV to 10 
MeV.  Plots of the specific interaction cross-sections for gold and tissue over this range 
are included in Appendix D.  Photon beams with energy levels relevant to therapeutic 
applications can interact with human tissue in one of three main ways – the photoelectric 
effect, Compton scattering, and pair production.  Although other modes of interaction are 
possible, the cross sections for human tissue only become statistically significant at 
energy levels that are several orders of magnitude higher, and so are assumed to be 
irrelevant in the scope of this work.  The three modes of interaction considered 
physiologically relevant are discussed below: 
 
1.3.1 Photoelectric effect 
 
An incoming photon beam interacts via the photoelectric effect by colliding with 
an orbital electron of a target atom.  The excited electron is ejected and an outer shell 
electron drops down to fill the vacancy.  This transition is accompanied by the emission 
of soft x-rays that are deposited in the immediate vicinity of the interaction.  Secondary 
emission occurs when the excited target atom returns to its ground state by emitting x-
rays and Auger electrons.  Ionization occurs due to the initially ejected electron as well as 
the subsequent Auger electrons.  Photoelectric effect cross sections are directly 
proportional to the number of electrons in the target and inversely proportional to the 
energy of the incoming beam as shown in Equation 1-1.   
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
 pe  C
Z 5
h 
3.5
 (1-1) 
 
As a result, low energy 

h  photon beams targeting high-Z materials produce 
significant localized dose due to the photoelectric effect.  Since gold is a high-Z material 
(Z = 79) compared to normal tissue (Z = 6–10), the photoelectric effect may have a 
profound impact on the localized effects of applied radiation.  The physical mechanism is 
illustrated in Fig. 1-3 and is most significant for beam energies below 100 keV.  This is 
evident as the K-edge for gold exists at 80.7 keV as described in Table D-1 in Appendix 
D.  Several brachytherapy sources have gamma emission spectra in the low keV energy 
range and so mostly interact with target tissues through the photoelectric effect. Beams 
that have lost their energy due to other interactions can interact through the photoelectric 
effect as well, so it is a relevant interaction mechanism for all radiotherapy beam 
energies. 
 
 
1.3.2 Compton scattering 
 
Photon beams undergo Compton Scattering when an incoming photon collides 
with an outer shell, or free, electron in the target material.  Contrary to the photoelectric 
effect in which the photon energy is almost completely absorbed by the target electron, 
Compton Scattering involves the scattering of both the incident photon and the target 
Figure 1-3: Photoelectric effect 
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electron.  The scattered electron can cause localized ionization while the scattered photon 
can undergo further interactions in the target material depending on the amount of energy 
it carries away from the collision.  Although the Compton Scattering cross section is 
directly proportional to the number of electrons in the target atom, the dependence is 
linear as given in Equation 1-2. 
 
 

c C  Z  (1-2) 
 
The physical mechanism associated with Compton Scattering is shown in Fig. 1-4 
and can be compared to the Photoelectric effect described earlier.  Due to the excess 
energy carried by the incident photon, it is scattered off the target atom instead of being 
absorbed as in the photoelectric effect shown in Fig. 1-3.  While there is no explicit 
energy dependence show in Equation 1-2, the cross sections for Compton Scattering 
interactions dominate in the photon energy range most prevalent in radiotherapy 
applications.  The cross-sections plotted in Figs. D-1 and D-2 show that Compton 
Scattering becomes the primary mode of interaction for photon energies in the 600 keV to 
50 MeV range for pure gold, and between 30 keV and 3 MeV for healthy tissue.  X-ray 
beams primarily used in teletherapy applications have an energy range of 1-20 MeV, and 
Compton Scattering cross sections dominate calculations of total absorption cross 
sections in that energy range.  
 
Figure 1-4: Compton scattering  
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1.3.3 Electron-positron pair production 
 
This mechanism involves the interaction of an incident photon with the nucleus of 
a target atom instead of an electron.  The incident photon collides with the nucleus and 
transfers all of its energy to the target.  An electron and positron pair is ejected as a result 
of this collision, and each particle causes ionization in the surrounding tissue.  As an 
antimatter particle, a positron cannot exist freely and collision with a free electron causes 
annihilation and two photons are produced that scatter in opposite directions.  The cross 
section for pair production is directly proportional to the square of the atomic number of 
the target, as shown in Equation 1-3. 
 
 

c C  Z
2 (1-3) 
 
Due to the creation of the electron-positron pair, the cross-section for this 
mechanism has inherently associated threshold energy and is described below in Fig. 1-5.  
The energy threshold is equal to the sum of the rest masses of the electron and the 
positron, namely 1.02 MeV.  The cross-sections increase as photon energy increases as 
described in the figures in Appendix D, but this process is not possible for incident 
photons with lower energy levels.  The energy of the subsequently generated photons 
depends on the energy of the incident beam as it is imparted to the ion pair produced, and 
these secondary photons may then undergo further interactions in the target material 
based on their energy levels.   
 
 
Figure 1-5: Electron / positron pair production  
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1.3.4 KERMA approximation and mass attenuation coefficient 
 
 The calculation of total mass attenuation coefficients is more useful to 
radiological applications than the individual interaction cross sections mentioned above.  
The benefit of calculating a single set of energy-dependent coefficients stems from the 
fact that it can then be used as a set of weighting factors when calculating the effects of 
photon beams incident on tissue.  Since the component cross sections are dependent on 
the atomic number of the target material, the overall mass attenuation coefficient has a 
similar dependence.  This dependence is what allows for the development of high-Z 
contrast materials for imaging and treatment purposes.  The difference in the mass 
attenuation coefficients for gold and tissue are shown in Fig. 1-6; the total attenuation 
coefficients are plotted as a function of photon energy and include the three interaction 
mechanisms discussed above.  The work described here makes use of the fact that the 
attenuation coefficients for gold and tissue differ by an order of magnitude or more over 
the range of photon energies normally available in hospital settings.  Attenuation 
coefficient data is available from [14]. 
Figure 1-6: Difference in attenuation coefficients for gold and tissue 
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 A quantitative method to estimate the amount of energy deposited as a result of 
the photon interactions described above is the KERMA approximation.  KERMA is an 
acronym for the sum of all Kinetic Energies of those primary charged particles Released 
by photons per unit MAss as defined in ICRU Report 33 [15].  This approximation 
assumes that any electrons induced by the incident photon beam come to rest in 
proximity to the interaction site and all primary electron-induced photons escape.  It 
ignores any energy deposition due to any secondary charged particles and takes into 
account the cross-sections for the photoelectric effect, incoherent Compton scattering, 
and pair-production as seen in Equations 1-4 and 1-5 as described by Hubbell et al. [16].  
However, it is important to note that the energy of the incident photon beam itself does 
not factor into the energy deposited other than the associated changes in interaction cross-
sections. 
 
 

KERMA  E
tr

 (1-4) 
 

tr


f pe pe  fcs cs  f pp pp 

 (1-5) 
 
As seen above, the coefficients can be calculated by taking the product of the 
photon fluence, the photon energy, and the mass-energy transfer coefficient 

tr   
described in Equation 1-5.  Consistent with the definition of the KERMA approximation, 
secondary photons and associated electrons are ignored in Equation 1-4.  The f factors in 
Equation 1-5 represent the average fraction of photon energy that is transferred to the 
kinetic energy of charged particles in the other possible interactions and are given below 
in Table 1-3.  The energy dependence of each of the interaction mechanisms is also 
evident in the expressions given below.  The fluorescence energy  depends on the 
distribution of electron vacancies produced during the interaction in question.   
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Table 1-3: Energy transfer fractions for calculating 

tr   
Interaction f factor 
Photoelectric effect 

f pe 1  E  
Compton Scattering 

fcs 1 E    E  
Pair Production 

f pp 1 2 mc
2 E  
 
An alternative method of calculating energy deposition at photon interaction sites 
involves calculating mass-energy absorption cross sections.  This method assumes that 
not all of the primary electron energy is deposited locally and is quantitatively 
represented by the (1–g) correction factor in Equation 1-6 where the value of g depends 
on the incident photon energy and the type of interaction.  The relevant equations for g 
are given in [16] and significant errors become apparent for photon energies higher than 
100 keV as seen in the figures included in Appendix D. 
 
 

en   1 g tr   (1-6) 
 
The two different approaches used to model the relevant physics in the Monte 
Carlo (MC) simulations described in this work can be compared to the two different 
methods described above.  The preliminary MC models described in Chapter 4 
approximate charged particle transport and so represent a small improvement on the 
KERMA approximation discussed here.  The detailed models described in Chapter 5 use 
more detailed particle transport and thus incorporate improved physical accuracy.  Details 
of the individual tallies used to record the results of the Monte Carlo simulation and 
specifics of the simulation code used, are discussed in Chapter 3.  The argument is made 
for both the track-length average method of calculating energy deposition, as well as, the 
pulse-height detector approach. 
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Chapter 2 
Literature survey 
 
 
Since the physiological significance of the work presented here depends on the 
use of gold in clinical settings, it is prudent to review the various properties and 
biological applications of gold presently available in previous publications.  The plethora 
of information available for gold is due to the fact that it has been considered a precious 
metal since the beginning of recorded history and has been used as a coinage standard 
and symbol of monetary wealth through the ages.  In more recent times, its favorable 
physical and chemical properties have made it an attractive material option for various 
electronic, chemical, and biomedical applications.  Furthermore, the recent explosion of 
interest in nanotechnology has led to a proportional increase in interest for precious 
metals including gold.   
 
In the context of cancer treatment, gold has been primarily utilized in the scope of 
nanobiology and nanomedicine.  Despite studies showing bulk gold to be biologically 
inert, various studies on gold nanostructure formulations have shown nano-gold to be 
inconsistently biocompatible depending on particle size and shape [17].  However, 
studies have shown several formulations with minimal inherent cytotoxicity and no 
stress-induced release of cytokines, indicating a well-defined window available for 
further research [18].   
 
In addition to the passive targeting studies presented in this chapter, several 
studies have been published on the use of monoclonal antibodies to transport species of 
interest to targeted tumor sites.  Monoclonal antibodies have the benefit of being targeted 
to specific extra-cellular markers on the surfaces of tumor cells.  As a result, using these 
targeted antibodies can result in preferential accumulation of the gold nanoparticles at 
tumor sites with minimal accumulation in healthy tissue.  This idea is discussed briefly in 
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this section and it is suggested that future work may extend the results presented here to 
include the improved tumor targeting available. 
 
Since the proposal to use gold as a radio-sensitizing agent requires an in vivo 
concentration of nanoparticles, the various physical and chemical properties of the gold 
formulations must be well characterized.  Given the extensive use of metallic gold, and 
the increasingly extensive use of gold nanostructures, these properties have been well 
documented and those relevant to this work are discussed below.  Furthermore, the 
biocompatibility of specific nanostructures is also an important design consideration and 
the size- and shape-dependent factors leading to in vivo compatibility are discussed here.  
However, a key assumption for the work presented here depends on the biocompatibility 
of gold nanostructures.  These properties are discussed below along with several passive 
and active mechanisms for specific tumor targeting of gold nanoparticles. 
 
 
2.1 Physical, chemical, and nuclear properties 
 
Bulk gold is a dense, lustrous, diamagnetic, transition metal that resists oxidative 
corrosion in both air and water.  Although not chemically inert, it is the least chemically 
reactive of all metals and, in its pure form, is non-reactive to all body chemistries as it 
resists attack by all biologically relevant acids.  It is the most electronegative metallic 
element, accounting for its lack of reactivity, and is one of the densest metals, 

 19.30 g
cm3
.  The face-centered-cubic crystalline structure of gold results in a highly 
malleable and ductile nature, leading to relatively easy manipulation and well-ordered 
nanostructure formulation [19].  Most medical applications of gold are a result of the 
unique properties that emerge when dealing with nano-scale gold.  These properties are 
often size-dependent and can be tuned to the specific application in question.  
 
 There are several physical property changes that can be expected as formulation 
size is decreased from the macroscopic scale to the nanometer scale.  Obviously, as 
particle radius decreases, surface area increases dramatically relative to volume as 
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described in Equation 2-1.  Associated with this increase in surface area and the 
corresponding increase in surface curvature, the melting point of nano-gold can be 
significantly lower than that of bulk gold [20].   
 
 Surface area to volume ratio: 

SA
V

4r2
4
3
r3

3
r
 (2-1) 
 
Aside from these expected changes, one peculiar property change that occurs at 
smaller particle sizes is the emergence of magnetism.  Although this change has not yet 
been seen in gold, it has been observed in nano-clusters of aluminum that is also non-
magnetic in bulk form.  Magnetic properties of nanoparticles have been used in several 
formulations and may prove useful for future studies with gold if the property can be 
identified in nano-gold.  The increase in surface area will be significantly important in 
this proposal, as the amount of targeting ligands that can be adsorbed to the surface will 
be directly proportional to the particle surface area.  Similarly, the amount of monoclonal 
antibodies that can be attached to gold, or vice versa, is a direct result of the relative sizes 
of these species.  Additionally, as particle surface area increases, the probability of self-
aggregation due to environmental triggers also increases which affects the efficacy of 
certain formulations.  Consequently, property changes at the nano-scale become 
significant when determining the clinical significance of this study even if they are not 
directly utilized in the work given here. 
 
 In addition to physical property changes due to size reduction, there are several 
optical and electronic properties unique to nano-gold structures.  One of the optical 
properties of nano-gold, known since antiquity, deals with the interaction of specific 
wavelengths of light with the nanostructures.  As the size of the structure becomes 
smaller than the wavelength of the incident light, coherent oscillations of free electrons in 
the conduction band cause strong absorption of green light.  This effect causes nano-gold 
to appear red, though the color can be tuned by carefully controlling particle size.  The 
application of solutions of gold colloids of various sizes has been used to create vivid and 
brilliant colors in stained glass.  These effects, commonly referred to as the surface 
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plasmon band (SPB), were first quantitatively described by Mie in 1908 and all 
subsequent studies have correlated the original theory posited by Mie [21].  Colloid 
solutions of gold nanoparticles exhibit an SPB around 520nm making it incredibly useful 
for cellular imaging applications since it lies outside the near-UV range of biological 
autofluorescence [22].  The maximum wavelength and bandwidth of the SPB is 
dependent on particle structure and size making it possible to tune the detectable 
wavelength by changing the nanostructures [23].  This property can be extremely useful 
to generate real-time images of subjects undergoing studies involving the use of gold, 
including clinical applications of the work presented here, without disrupting the 
parameters of the study. 
 
 Related to the described plasmon resonance, several studies have also explored 
the possibility of self-fluorescence of gold nanoparticles in the absence of external 
stimuli.  Although a number of surface ligands have shown promise in their abilities to 
enhance this fluorescence, the scope of this study precludes detailed examination of these 
properties.  SPB-related effects may be sufficient in future work to track the distribution 
of gold nanoparticles in the body.  Similarly, studies concerning the size-dependent 
changes in the conductivity of gold are not discussed in this study. 
 
 As previously mentioned, gold is the most electronegative metal.  This directly 
leads to it being the least chemically reactive metal, and is the reason it resists attack by 
most acids.  The most common oxidation states of gold used in medical applications, 
Gold (I) and Gold (III), are stable in aqueous solution.  This stability, in addition to the 
fact that gold is resistant to corrosion in both air and water, makes gold formulations 
extremely attractive candidates for medical applications.  Biocompatibility and 
distribution studies, as well as specific uses of gold nanoparticles are described in detail 
later in this work. 
 
 The electronic configuration and nuclear structure of gold are the basis for its use 
as a contrast and radio-sensitizing agent in radiotherapy.  The fact that gold has 79 
protons and electrons makes it an ideal target for photoelectric-type interactions as pe 
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has a very strong atomic number dependence as seen in Equation 1-1.  When compared to 
healthy tissue that is mostly comprised of low Z elements such as hydrogen (Z=1), 
carbon (Z=6), nitrogen (Z=6), and oxygen (Z=8), gold can have a six to nine orders of 
magnitude higher cross section for the same photon energy.  The specific cross sections 
are compared in Appendix D. 
 
 
2.2 Structure and formulation 
 
Michael Faraday was the first to describe the formulation of gold nanoparticles, in 
1857, using a two-phase reduction of an aqueous solution of sodium tetrachloroaurate 
(Na[AuCl4]) with phosphorus as the reducing agent, dissolved in a solution of carbon 
disulfide.  His method yielded a wide distribution of particle sizes ranging from 3 nm to 
30 nm.  This was followed by the report by Turkevich of the now widely used citrate 
reduction method in which chloroauric acid (HAuCl4) is reduced using trisodium citrate 
[24].  The trisodium citrate acts as both the reducing agent and the stabilizing ligand and 
varying the relative concentrations of HAuCl4 and trisodium citrate results in very 
controlled nanoparticle sizes up to 200 nm [25, 26].  Besides citrate-stabilized 
nanoparticles, a widely studied area of interest is in thiol-protected gold nanostructures 
due to the broad versatility of thiol-based conjugation chemistries. Brust and Schiffrin 
first described the generation of thiol-protected gold nanoparticles in 1994 using a two-
phase liquid-liquid system to form protected nanoparticles with diameters on the order of 
a few nanometers [27].   
 
Modifications to the Brust-Schiffrin method have used a wide variety of other 
organic ligands to stabilize the gold nanoparticles including amines, phosphines, 
carboxylates, proteins, DNA, enzymes, and small drug molecules [28-32].  As polymer 
stabilization has been reported to greatly increase blood circulation times of 
nanoparticles, use of this mechanism looks promising for the purposes of this work.  
Polymers used as „stealthing‟ ligands have included poly(vinyl pyridine), poly(ethylene 
glycol), poly(N-isopropyl acrylamide), and poly(methyl methacrylate) [33-38].  While the 
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specific properties of the polymers are different, the overall effects are similar in that the 
gold nanoparticles display monodispersity in vitro, are protected from self-aggregation in 
vivo, and have prolonged circulation times in the blood. 
 
 
2.3 Cytotoxicity and biodistribution studies 
 
Several toxicological studies on nanoparticle applications have been reported in 
various studies.  These studies have used Inductively Coupled Plasma (ICP) 
Spectroscopy to determine and quantify the distribution of the gold nanoparticles.  ICP 
Atomic Emission Spectroscopy (ICP-AES) uses the characteristic wavelengths of excited 
ions to determine the presence of specific metals in a sample.  Along the same lines, ICP 
Mass Spectroscopy (ICP-MS) uses ICP to generate ions in the sample that are then 
separated and quantified using a coupled mass spectrometer.  By isolating specific organs 
after gold nanoparticle treatment, the amount of gold present in the tissue can be 
determined by ACP-AES or ACP-MS after acid digestion of the tissue.  These methods 
were primarily used to determine the amount of gold uptake in the distribution studies 
given below. 
 
A recent review by Alkilany and Murphy contained a comprehensive summary of 
research done on the in vitro and in vivo cytotoxicity of gold nanoparticles [18].  The 
review included toxicity results for gold nano-spheres ranging in diameter from 0.8 nm to 
250 nm, and nano-rods ranging in size from 40 nm x 18 nm to 65 nm x 15 nm.  
According to the studies reviewed, gold nano-spheres with a range of sizes (4, 12, and 18 
nm in diameter) and surface moieties (citrate, cysteine, glucose, biotin, and 
cetyltrimethylammonium bromide (CTAB)) are non-toxic to human leukemia cell lines 
[39].  Further work describes the non-toxicity of spheres with 3.5 nm and 10 nm 
diameters to human immune cell lines [40].  In addition, nanoparticles smaller than 2 nm 
in diameter are toxic and show chemical reactivity, possibly due to surface agents, that 
are not present at larger sizes [41-43].  In vivo studies of nanoparticle size effect on 
toxicity, however, illustrate very different results.  
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Work done by Chen et al. showed both small (3 and 5 nm diameter) and large (50 
and 100 nm diameter) nanoparticles are not toxic in mice while intermediate sizes (8 – 37 
nm diameter) had lethal effects as shown in Fig. 2-1 below [44].  As a result, there is a 
window of in vivo toxicity for gold nanoparticle that can be avoided to develop effective 
delivery systems.  Fortunately, work done by Chithrani et al. described receptor-mediated 
endocytosis (RME) as the primary mechanism for cellular uptake and maximal cellular 
uptake for transferring-coated gold nano-spheres with a diameter of 50 nm [12, 45].  
Since this maximal uptake diameter falls outside the toxic window, the detailed models 
described in Chapter 5 used nanoparticle sizes of 50 nm to determine dose enhancement. 
 
 
 
 
 
2.4 Active targeting strategies 
 
While work to improve passive targeting of tumor cells is ongoing, significant 
effort is being made to develop active targeting methods as well.  A large amount of 
research is being undertaken on the use of monoclonal antibodies (mAb) to bind to tumor 
Figure 2-1: in vivo toxicity as a function of nanoparticle diameter.  
Only particle sizes between 8 and 27 nm displayed toxicity. [44] 
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cell surfaces in an effort to recruit the immune system and administered pharmaceutical 
agents to the target.  The immune system normally responds to foreign species by 
differentiating between native and non-native.  Since tumor cells are essentially native to 
the patient, the normal immune response is insufficient to attack these cells.  However, 
due to cell cycle and proliferation irregularities, tumor cells display several unusual 
antigens that may be used to target these cells.  Since these antigens are physiologically 
inappropriate based on cell type, antibodies specifically tailored to those antigens may be 
used to ensure specific delivery of therapeutic agents.   
 
The benefit of using monoclonal antibodies to transport gold nanoparticles to tumor 
sites can result in significant accumulation in tumor cells while minimizing the diffusion 
into healthy cells.  As mentioned earlier, the Enhanced Permeation and Retention (EPR) 
mechanism can be used to transport any nanoscale particles to tumor sites.  Without 
active targeting, however, there is still a chance that the gold may undergo cellular uptake 
into the surrounding healthy cells instead of specifically into the targeted tumor cells.  
Labeling gold with appropriate monoclonal antibodies can result in specific binding to 
the extracellular markers of tumor cells and therefore specific uptake into the targeted 
tumor cells.  This mechanism has been used to specifically direct chemotherapeutic 
agents and can be similarly used to direct the gold nanoparticles.   
 
As shown in Fig. 2-2 below, several different treatment options become available 
once the antigens displayed on the tumor cell surface have been correctly identified and 
the corresponding antibodies have been conjugated to the treatment agent [46].  A 
cursory literature survey yielded over 200 monoclonal antibodies that have been 
approved or being investigated for clinical use.  As a result, it is becoming increasingly 
possible to accurately determine which antibody may be necessary to specifically target 
tumor cells without any passive leakage of the therapeutic agent into neighboring healthy 
cells.  The effects of minimizing passive diffusion are discussed below in Chapter 5, and 
it may be possible to entirely prevent this diffusion with appropriate use of a monoclonal 
antibody conjugation in the future. 
 
 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5 History and current applications 
 
Although Faraday described the formulation of gold nanoparticles as early as 
1857, the use of gold for medical applications was not posited until German physician 
and microbiologist Robert Koch first highlighted the possibility in 1905 when he 
described the antibacterial effects of gold cyanide on tubercle bacilli [47].  His discovery 
led to further research in gold compounds for medicinal purposes and, in 1929, French 
physician Jacques Forestier published his seminal work on the anti-arthritic activity of 
gold compounds [48].  Since the 1970s there has been considerable interest in the 
relevant biochemistries of gold complexes and research has included the use of gold salts 
to treat rheumatoid arthritis, colloidal gold solutions as in situ imaging agents, gold 
nanoparticle probes as biological markers, and radiolabeled gold particles as therapeutic 
agents for cancer treatment [49, 50].  Gold‟s high density, very high electrical 
Figure 2-2: Active nanoparticle targeting using mAb. Multiple therapeutic agents 
can be conjugated to mAb to specifically target a tumor cell.  Adapted from [46]. 
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conductivity, and electron production ability also lend it to scanning electron microscopy 
applications for improved spatial resolution [51].   
 
Although gold has been the focus of widespread research for several decades in 
the fields of cancer imaging and treatment, only recently has it been used in conjunction 
with the advances of nanomaterial research.  Gold nanostructure assembly can be very 
tightly tuned to develop a variety of structures including nanoparticles, nanorods, 
nanocages, and nanoshells with sizes controlled on the order of nanometers.  Due to the 
relative ease of fabrication, several studies have been conducted to test the 
biocompatibility of various gold nanostructure formulations and optimal ranges have 
been established for particle size, shape, and aspect ratio.  In addition, due to the ease 
with which ligands can be conjugated to the surface of structures, many different surface 
modifications have been studied for therapeutic and diagnostic applications.  Gold has 
shown promise in drug targeting applications due to its affinity for surface adsorbed 
proteins, and in imaging applications due to its uniquely tunable optical characteristics 
using Raman scattering. 
 
2.5.1 Nanomedicine 
 
Bio-nanotechnological advances have resulted in relatively widespread use of 
gold nanoparticles.  Molecular labeling using AuNP has been a popular choice for 
developing sensitive detection techniques.  As mentioned earlier, a variety of species can 
be adsorbed to the surface of nanoparticles including antibodies, peptides, and proteins 
[32, 51, 52].  The optical properties of gold nanoparticles, when differentiated from 
naturally fluorescent biological molecules, can provide significant improvement in the 
detection schemes.  Additionally, since these optical properties are dependent on particle 
size and aspect ratio, the assays can be finely tuned depending on the target [53].  The 
possibilities of being able to image drug delivery in real time have led to increasing 
interest in „theranostic‟ applications in which therapy and diagnosis are combined into the 
same overall treatment scheme. 
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 Due to the many favorable properties of gold at the nano-scale, AuNPs have 
become increasingly popular as delivery agents to regulate biological processes as of late 
[54].  Kumar et al. described an intracellular imaging platform utilizing multifunctional 
AuNPs that combined imaging and cytosolic drug delivery [55].  These „nanosensors‟ 
included antibodies specific to actin and biotin to induce the binding capacity of the 
AuNP, and successful targeting resulted in the expression of an optical signal.  Similarly, 
Chan et al. demonstrated the down-regulation of a receptor over-expressed in several 
breast cancers using antibody-conjugated AuNPs using the mechanisms for monoclonal 
antibody AuNP tagging that were discussed earlier [56].  Eghtedari et al. appended PEG 
molecules to similar antibody-conjugated AuNP to increase their stability in vivo and 
extend particle lifetime in blood [57].   
 
A visual representation of a multifunctional gold nanoparticle is shown below in 
Fig. 2-3.  Here, several functional moieties are displayed on the surface of the AuNP with 
targeting and delivery capabilities.  Ideally, the target cells preferentially express the cell 
surface markers for the included antibodies and therefore, accumulate the AuNP 
exclusively.  Once the cell-surface antigens recruit the AuNP, the delivery peptides can 
be cleaved to induce optical signals or deliver drugs. 
 
 
Figure 2-3: Multifunctional AuNP designed for targeting, delivery and 
imaging. [Adapted from 55] 
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2.5.2 Drug delivery 
 
In addition to cell labeling, AuNPs may also serve as drug vectors if designed to 
be stable in the circulatory system, but lose stability when the target organ is reached 
[58].  Since typical nanostructure synthesis involves citrate-stabilized intermediates, the 
overall surface charge tends to be negative [12].  This allows for favorable charge 
interactions with the amine domains of proteins and results in surface adsorption of 
proteins. This in turn, results in an improved ability to cross cell membranes and 
therefore an improved ability to deliver coupled drug molecules to intracellular spaces.  
Additionally, it is this adsorption ability that is used to conjugate the various antibody 
markers to the nanostructure surface as mentioned previously.  As a result, highly 
specific targeting can be achieved using surface markers that may be unique to the target 
in question. 
 
The discussed membrane interactions are only relevant if the drug vectors are able 
to reach the target site.  As a result, the EPR effects discussed above become necessary 
considerations when designed delivery systems for targeting tumors.  For nuclear 
targeting to be possible, particle influx through nuclear pores must be possible, which 
only occurs for particles that are less than 40nm in diameter [59].  Work by Feldherr et al. 
has shown the utility of gold nanoparticles as efficient vectors for both intracellular and 
nuclear delivery [60-62].  Conjugating known nuclear localization signals to particle 
surfaces results in facilitated particle uptake via receptor-mediated endocytosis [63].  
Other examples of drug delivery vector design have involved the use of AuNP-peptide 
complexes to create multifunctional vectors.  Tkachenko et al. used bovine serum 
albumin coupled to AuNP surfaces to successfully target HepG2 human hepatocarcinoma 
cells [30].  Future work may incorporate the therapeutic applications discussed here with 
the gold-mediated mechanisms described in this work. 
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2.5.3 Imaging 
 
 Gold nanoparticles are promising candidates in photo-diagnostic applications 
because of their tunable optical properties, ease and robustness of conjugation and 
appreciable biocompatibility [18, 58, 64]. For the past two decades, detection methods 
have been based on either particle aggregation, changes in local refractive index or 
vibrational differences in surface-enhanced Raman scattering [54].  Colorimetric assays, 
for instance, based on a red shift upon nanoparticle aggregation, are extremely sensitive 
in comparison to conventional methods based on molecular fluorophores. Mirkin and 
others have taken advantage of this method to detect sub-picomolar levels of 
oligonucleotide, DNA binders and cancer cells in vitro.  An example of these favorable 
aggregation interactions can be seen in Fig. 2-4, from the works of Mirkin et al. [65-67].  
Although the use of gold nanoparticles is limited in clinical settings due to specificity and 
toxicity concerns, it is conceivable that improvements in those areas – several of which 
are discussed above – may result in these techniques being used to determine 
nanoparticle uptake during the various gold-mediated radiation studies described here. 
 
 
 
Figure 2-4: Colorimetric assay using gold nanoparticles. Images are 
based on aggregation-dependent red-shift [65] 
 33 
2.6 Studies using gold as a radio-sensitive agent 
 
The idea of using a high-Z element as a radio-sensitizer is not a new one.  
Matsudaira et al. first demonstrated the use of iodine as a radio-enhancer more than three 
decades ago [68].  Since then, there has been considerable interest in determining the 
specific impact of iodine as a contrast material for both imaging and therapeutic purposes 
with several in vivo and simulation studies generating promising results [69-72].  
Additional work has been to study the effects of gadolinium-based contrast agents as well 
to study the possibility of using the platinum-based chemotherapy agent Cisplatin as a 
possible contrast agent [72, 73].  While each of these studies has shown promise for the 
use of contrast agent mediated radiotherapy, several clinical issues arise when attempting 
to design treatment options using iodine contrast agents (low molecular weight leading to 
rapid clearance), Cisplatin (inherent cytotoxicity), or gadolinium contrast agents (low 
atomic number).  As a result, recent interest in using contrast media to improve radiation 
response has focused on the use of gold as the contrast agent. 
 
Gold has shown promise in radiation treatment applications as a radiosensitive 
material for dose enhancement in both surface and deep-tissue tumors.    The high-Z 
nature of gold (Z=79) means that it should have favorable interaction cross-sections for 
all scattering types compared to normal tumor tissue that is comprised primarily of 
oxygen (Z=8), hydrogen (Z=1), carbon (Z=6), and nitrogen (Z=7).  Therefore, it is 
theoretically possible to use site-specific gold to act as a type of amplifier for incident 
radiation as it would have a much higher affinity for photoelectric and scattering 
interactions, and correlated energy deposition, compared to the surrounding tissue.  
Previous studies have shown increases in local photon absorption of up to three orders of 
magnitude through the photoelectric effect using iodine and gadolinium [70, 71, 74, 75].  
Using gold as the contrast agent should yield similarly beneficial cross section 
improvements.  Given below is a brief review of the in vivo and simulation studies done 
in which a high-Z element has been used a radiosensitive agent.  
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2.6.1 In vivo and in vitro murine studies 
 
Hainfeld et al. reported what was potentially the first and most significant in vivo 
study of using gold as a radiosensitive agent in 2004 [76].  Mice displaying mammary 
carcinoma cells were injected with 1.9 nm gold nanoparticles (AuNP) and tumor 
accumulation of 7 mg of gold per gram of tumor tissue was observed.  Irradiation using 
250 kVp x-rays resulted in a 66% increase in one-year survival rates of cancer-bearing 
mice when compared to irradiation without the implanted gold.  Illustrating proof-of-
concept, this study was followed by several subsequent studies that attempted to validate 
these conclusions and further explain the mechanisms involved. 
 
Hainfeld et al. followed up their initial work with a subsequent murine study 
aimed at determining the utility of gold nanoparticles as contrast agents for x-ray imaging 
purposes [77].  Using similarly sized AuNP (1.9 nm), the study showed that there was 
extensive gold retention in the tumors after blood clearance due to the EPR effects.  Since 
gold has a three-fold higher absorbance at 100 keV compared to iodine, the study 
surmised a ten-fold or more increase in contrast gain when using gold as the contrast 
media.  The implication of this study are vast as it points to the possibility of using gold 
as both a real-time imaging contrast agent as well as a radiosensitive agent after tumor 
localization. 
 
The clinical applications of small-diameter nanoparticle studies like the two 
Hainfeld studies were cast in doubt by the work published by Butterworth et al. that 
demonstrated that 1.9 nm AuNP cause cell death by multiple mechanisms including 
increased apoptosis due to oxidative stress [78].  This observation had a two-fold 
implication.  On the one hand, it presented a problem when attempting to quantify the 
radio-sensitivity associated with small-diameter AuNP since cell death could be 
attributed to non-radiation related events.  On the other hand, the posited oxidative stress 
would result in a reduction of tumor hypoxia and therefore an increase in the inherent 
radiation sensitivity of the tumor.  Ultimately, the work confirmed earlier studies that 
stated that small diameter gold nanoparticles are toxic leading to the conclusion that 
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larger diameters must be investigated for gold-mediated radiotherapy [18, 44].  These 
findings confirmed the work published by Chen et al. describing the upper limit of the 
toxicity window, but were in disagreement on the lower bounds described earlier in Fig. 
2-1. 
 
In an effort to elucidate the effects of larger diameter AuNP, and to clarify the 
disagreements on nanoparticle size in earlier studies, Chithrani et al. demonstrated the 
effects of nanoparticle size on their effectiveness as radiosensitive agents [79].  Cellular 
uptake and corresponding radio-sensitivity of AuNP of three different diameters (14 nm, 
50 nm, and 74 nm) were compared in vitro for both low- and high-energy photon beams.  
The study, reiterating previous work, showed maximal cellular uptake for 50 nm gold 
nanoparticles [12].  Cells were then irradiated with 105 kVp, 220 kVp, 660 kVp, and 6 
MVp photon beams and the radiation-induced double-stranded DNA breaks were 
quantified using different cell-culture assays.  Dose enhancements of 66%, 43%, 18%, 
and 17% were observed respectively indicating that the increase in AuNP cellular uptake 
drastically improves radiation response even at higher photon energy levels.  The results 
of this study directed the decision to use 50 nm gold nanoparticles for the purposes of the 
detailed model described later in this work. 
 
2.6.2 Monte Carlo simulations 
 
In order to quantitatively corroborate the results of the above-mentioned in vivo 
studies, a series of Monte Carlo simulation studies have also been carried out for various 
contrast media.  These studies have focused on clarifying the mechanisms inherent in 
contrast media dose enhancement and have mostly assumed the physical parameters 
described in the in vivo studies mentioned. 
 
Though not related to gold, it is useful to mention a simulation study published by 
Robar et al. which examined the possibility of dose enhancement using gadolinium and 
iodine contrast agents [73].  The use of MeV photon beams was explored using Monte 
Carlo simulations, and the effects of beam flattening filters and contrast agent 
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concentrations were studied.  Although dose enhancement of up to 70% was seen with 
contrast media concentration of 1g/ml, such tumor concentrations are not clinically 
feasible.  For the potentially achievable concentration of 30 mg/ml, dose enhancement of 
up to 15.8% and 23.1% was seen for iodine and gadolinium respectively using a 2 MeV 
photon beam.  Smaller increases (3.9% and 4.4% respectively) were observed for high 
quality beams in the 10 MeV – 24 MeV range.  Although using less effective contrast 
agents, this study provided a quantitative framework in which to study future contrast 
materials. 
 
Following the seminal work by Hainfeld, and following the example of the Robar 
study, a series of Monte Carlo simulations have been conducted using various computer 
codes, target geometries, and contrast media.  Although the results have varied 
significantly depending on the specifics of the study, each simulation has borne out, to 
some degree, the general claim that gold nanospheres can act as radiation enhancing 
agents in clinical treatment settings and that they are more effective that previously 
studied gadolinium- and iodine-based materials. 
 
One of the first studies following Hainfeld‟s work was conducted by Cho to 
attempt to quantitatively validate the Hainfeld study [74].  Three different photon 
energies were tested for teletherapy applications and one brachytherapy setup was 
modeled as well.  Relatively modest dose enhancement was achieved for 4 MeV and 6 
MeV photon beams (3.2% and 7.4% respectively at maximum gold concentrations of 30 
mg/g).  However, a dose enhancement of between 200% and 550% was seen for a 140 
kVp photon beam (7 mg/g and 30 mg/g tissue-gold concentrations respectively).  Such 
significant dose enhancement has not been replicated in subsequent models and it has 
been theorized that neglecting to model discrete gold nanoparticle distributions may be 
the cause for the over-enhancement of the recorded dose [80].  For the brachytherapy 
model, dose enhancement of up to 30% was measured, and an improvement of at least 
2% was observed for every gold concentration when compared to similar concentrations 
of gadolinium contrast agents. 
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A subsequent study by Cho et al. was then published that sought to more precisely 
define the effects of AuNP in brachytherapy models [81].  Using a 50 kVp photon source, 
a I
125
 source, and a Yb
169
 source yielded macroscopic dose enhancement ranging from 
44% to 116%.  Using a tumor-gold concentration of 18 mg/g, the broad photon energy 
spectrum of Yb
169
 yielded the highest dose enhancement suggesting that the photons may 
be interacting at multiple orbital-edge energy levels. 
  
Most recently, Garnica-Garza assumed CM concentrations of 10 mg/g and used 
the electron-photon coupled transport MC code PENELOPE with an optimization 
algorithm to obtain a dose enhancement of 38% for a prostate cancer model [72].  This 
model assumed a uniform concentration of gadolinium in the tumor, and explored 
contrast agent leakage, and non-uniform loading of the tumor.  While using gadolinium 
instead of gold, this study did attempt to model a physiologically accurate simulation 
geometry and measure doses delivered to non-tumor volumes. 
 
The results of these published Monte Carlo studies were used to direct the 
development of the MC simulations described in this work.  The code, geometric models, 
and physical parameters are described in the chapters that follow.  The preliminary model 
assumes the physical parameters of the first Hainfeld study, and extends the work done 
by Cho by detailing several teletherapy schemes.  The effects of varying photon beam 
energy, in situ gold concentration, and tumor depth are explored in detail.  The detailed 
model integrates the cell uptake results published by Chithrani et al. and attempts to 
quantitatively model the in vitro results described in the study described earlier.  The 
effects of non-homogenous gold distribution and lack of nanoparticle specificity are also 
explored in this model.  Both Monte Carlo models represent an improvement in scope 
and detail compared to the studies referenced above and should provide a detailed 
framework for in vivo and phantom studies to follow. 
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Chapter 3 
Motivation for MCNP5 simulations of radiation-tumor interaction 
 
 
In order to determine the effects of using gold to improve dose response at a 
tumor site, several Monte Carlo simulations were run using MCNP5 – the particle 
transport code developed and maintained by Los Alamos National Laboratory [82].  
Several published studies have shown an in vivo improvement of tumor mitigation in 
murine models accompanied by relatively limited quantitative modeling data.  As a 
result, a comprehensive MC model was developed in order to try and quantitatively 
corroborate the qualitative results shown in the Hainfeld and Chithrani studies [76, 79] 
and the quantitative results shown elsewhere [74, 81].   
 
A preliminary model was first developed to clarify the variables having a 
significant impact on the radiation dose delivered at a specified tumor site.  Hainfeld 
reported possible dose enhancement at in situ gold concentrations of 0.7% - 1.2% by 
mass [76].  Additionally, Robar et al. reported contrast media concentrations approaching 
3% by mass [73].  These physical parameters were used as the framework for the 
preliminary model.  Cho et al. only reported source strength dependence for 
brachytherapy applications [74]; the preliminary model described in Chapter 4 illustrates 
the effects of varying the energy spectra of external photon beams.  Work done by Van 
den Heuvel discussed beam energy considerations but used water as the background 
media [83].  The results obtained in this work should reflect a more accurate biological 
model as described in Chapter 4.   
 
  The majority of reviewed MC studies have measured the effects of the gold 
concentrations originally published in the Hainfeld studies.  However, the Chithrani study 
showed significant improvement in cellular uptake with larger (50 nm) nanospheres, and 
subsequently reported different gold concentrations [79].  As a result, the detailed model 
factored updated in situ gold concentrations, as well as, non-homogenous gold 
distribution, resulting from lack of nanoparticle penetration, and non-specific 
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nanoparticle targeting.  The relative importance of each component was studied to 
determine the significant factors.   
 
Although the specifics of each model differ, the physical quantities measured and 
the method of comparing gold-containing tumor tissue, bare tumor tissue, and healthy 
tissue remain the same.  Internal material specifications differ among models depending 
on the variable being tested, but the geometry for each case assumes a rectangular prism 
of tissue.  A parallel beam of photons incident on one face of the prism is simulated such 
that the tissue slabs present orthogonally to the beam axis.  Detailed diagrams of the 
geometries used in each model are given in Appendix A.  MCNP5 allows for the 
measurement of various tallies in given target cells and three different tallies were used 
over the course of these simulations.  The results for the F4 and F6 tallies were recorded 
for the preliminary models, while the results for the modified F8 tally were recorded for 
the detailed model.  A description of the tallies used is given below. 
 
 
3.1 MCNP5 Tallies  
 
The first tally used in this work is the F4 tally that measures particle flux due to 
each incident photon in units of particles/cm
3
.  Equation 3-1 describes the physical 
quantity measured and values are scored as particle weight multiplied by track-length per 
unit volume.  Since 

N
r 
r ,E,t ds can be interpreted as the track length density, the average 
flux can be estimated by summing the track lengths over all photon energies over a 
specified volume.  Tracking a large number of particle histories results in a large number 
of contributions to this tally leading to increased reliability for the track length estimate.   
 
Table 3-1: Relevant equations for F4 particle flux tally 
Tally Score Physical quantity Eq. 
F4 

W
Tl
V
 

V 
1
V
 dE  dt  dV  d
r 
r ,,E,t 

1
V
 dE  dV  ds N
r 
r ,E,t   
(3-1) 
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 The second tally used is the F6 tally that measures energy deposition per unit 
mass in each tissue cell by using track length measurements convolved with a heating 
function as given by Equation 3-2.  This heating function is obtained by summing the 
average energy deposition for all particle interactions at a given particle energy and is 
given by Equation 3-3.  As mentioned earlier, using this heating function method with the 
simplified physics model is analogous to applying the KERMA approximation discussed 
in Chapter 1 since the electrons are assumed to deposit their energy locally.  Energy 
deposition for this tally is measured in units of MeV/g and the tally is scored as particle 
weight multiplied by track length and atomic density per unit mass weighted by the 
interaction cross-sections and the heating function. 
 
 
Table 3-2: Relevant equations for F6 energy deposition tally 
Tally Score Physical quantity Eq. 
F6 

W Tl t E H E 
a
m
 

H t 
a
m
 dE  dt  dV  d t E H E 
r 
r ,,E, t 
 

H E  E  pi E  E i,out E  
i1
3

 
(3-2) 
 
(3-3) 
 
 
   Finally, the third tally used was the modified F8 tally that measures energy 
deposition by performing a pulse height count.  Instead of recording particle track length, 
the results of this tally are analogous to the counts recorded by a physical detector.  The 
tally maintains an energy account for each cell and adds or subtracts energy based on the 
number and energy of particles crossing the boundaries of a cell.  Since the kinetic energy 
of each particle is recorded, neglecting electron transport results in the KERMA 
approximation while accounting for electron transport should result in a more physically 
accurate measurement of effective dose if the inherent microscopic approximations in 
MCNP5 are overcome.  The results from this tally were divided by the mass of each cell 
to obtain units of MeV/g analogous to those obtained from the F6 tally.  Equation 3-4 
describes the calculations performed to generate the tally results in MCNP5. 
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Table 3-3: Relevant equation for *F8 modified pulse height tally 
Tally Score Physical quantity Eq. 
*F8 

ED WC  Pulses binned at discrete energy levels (3-4) 
 
 
The constants and variables used in Equations 3-1 through 3-4 are given in Table 
3-4 below.  The tally values for healthy tissue, in the absence of gold, were taken to be 
the baseline against which the various other simulations were compared to calculate the 
dose enhancement factor using Equation 3-5 given below. 
 
 
Table 3-4: Variables and constants used to calculate F4, F6, and *F8 tallies 

W  = Particle weight 

WC  = Collective weight for a particle history 

Tl  = Track length (cm) 

V  = Volume (cm
3
) 

r 
r , ˆ ,E,t  = Position vector (cm), direction vector, energy (MeV), time (10
-8 
s) 

V  = Average flux in a cell 

Ht  = Total energy deposition in a cell (MeV/g) 

 t E  = Total microscopic cross section (barns) 

H E  = Heating number (MeV/collision) 

ED  = Total energy deposited by a particle history 

a  = Atomic density (atoms/barn-cm) 

m  = Cell mass (g) 

  = Angular flux 

pi(E) = 
Probability of interaction at energy E 

i 1 Compton scattering 

i  2 Pair production 

i  3 Photoelectric absorption 

E i,out E  = Average exiting gamma energy for interaction i at energy E. 
 
 Although only three main photon interactions are listed at the bottom of Table 3-
4, other interaction probabilities may be considered for photon energies high enough to 
have significant cross-sections for those interactions. 
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3.2 Effective Dose Enhancement Factor 
 
The primary quantitative tool used to analyze the results of the difference cases 
was the calculation of a localized Dose Enhancement Factor (DEF).  This factor was 
determined by comparing the amount of energy deposited in each slab in the presence of 
gold (EAu) against the baseline (EB).  This ratio was then used to determine whether 
adding gold to the tumor site had any effect on improving the radiation response at the 
tumor site.  The equation used to calculate DEF is given below. 
 
 

DEF 
Energy deposited in tissue layer containing gold
Energy deposited in bare tissue layer

EAu
EB
 (3-5) 
 
The results of Equation 3-5 were then recorded as a function of distance in each 
simulation and the results were plotted below for the different variables tested.  A DEF 
value of 1 indicates no change in the amount of dose received compared to normal, 
healthy tissue.  A DEF value greater than 1 indicates an increase in the effective dose for 
a particular tissue cell, while a value less than 1 indicates a decrease in the dose. 
 
 
3.3 Preliminary Monte Carlo Model 
 
The preliminary model used to obtain the results discussed in Chapter 4 is an 
approximation of actual human physiology.  However, the geometry used should be 
sufficient to demonstrate the significant physics applicable for this treatment approach, 
and to evaluate the geometrical effects on effective dose estimates.  In order to model a 
deep-tissue tumor, simple slab geometry was used.  A rectangular prism with a side 
length of 20 centimeters was used to represent the subject tissue (phantom) as shown in 
Fig. 3-1.  Although the size of the phantom exceeds most physiological dimensions, it 
was chosen in order to get insight on effects of tumor depth on dose enhancement.  In 
order to determine any depth dependence, the phantom was split into 2 cm thick slabs 
with identical material properties and dimensions.  All tissue compositions were 
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referenced from Report 89 of International Council of Radiation Protection and are 
summarized in the attached appendices [84].  For the purposes of this model, the 
composition of tumor tissue was taken to be the same as that of healthy muscle tissue.  As 
a result, the only differences in material composition for any given simulation of this 
model were due to the presence of a specified concentration of gold within a slab.  The 
gold was assumed to be colloidal and distributed homogenously throughout the specified 
tissue slab.   
 
 
Three different simulations were run using this model.  In each case, one of the 
variables was modified in order to ascertain the relative effects of the variable on the dose 
received by the target cells.  The variables tested in the preliminary model include beam 
energy, tumor depth, and in situ gold concentration.  The results of the preliminary 
models were used to guide the development of the detailed model, as the relevant 
boundary conditions for the variables were determined.  For the purposes of the 
preliminary model, the thick-target bremsstrahlung (TTB) approximation is used and 
primary electrons are assumed to slow down locally.  However, secondary photons are 
not ignored in this model making it better than the simple KERMA approximation.  
Electron transport is not ignored in the detailed model, as described below, which 
furthers improves the physical accuracy of the model. 
 
Figure 3-1: Geometry used in preliminary model MCNP simulations 
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3.4 Detailed Monte Carlo Model 
 
 The depth dependence simulations were designed to illustrate the importance of 
limiting the amount of tissue present between the incident surface and the targeted tumor.  
Since the gold contrast media effectively shields the tissue behind the tumor from excess 
radiation, the photon beam deposits significantly less energy after encountering the tumor 
volume.  For these reasons, this detailed model does not vary the depth of the simulated 
tumor with the assumption that clinical teletherapy schemes would be designed to make 
use of the most efficient beam geometry to minimize the depth of the tumor.  However, 
the overall size of the tissue model is reduced to better approximate physiological 
dimensions and a 0.5 cm skin layer is added.  Additionally, the resolution of the model is 
improved to include 1 cm slices throughout and further improved to 0.25 cm sliced 
within the tumor boundaries.  As a result, the overall model geometry is a refined version 
of the preliminary model and is shown in Fig. 3-2 below.  
 
 
In an effort to improve the physical accuracy of the detailed model, both photon 
and electron transport was taken into account.  Both primary and secondary photons are 
accounted in this model since primary electron transport was fully tracked.  This results 
in significant improvement over the preliminary model where secondary photons were 
tracked but electrons were not, and further improvement over a KERMA approximation 
where all electron energy is locally deposited.  As described above, the modified F8 tally 
Figure 3-2: Geometry used in detailed model simulations 
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was used to model the improvement in the physical approximations as all energy 
deposition in a target cell is recorded.  As both photon and electron transport are 
included, the results of this tally should be more accurate than the earlier assumptions.  In 
order to gauge the level of improvement, the concentration dependence model was run 
using the new geometric parameters mentioned above.  Higher gold concentrations were 
calculated from the descriptions of the Chithrani study discussed in detail in Chapter 5.   
 
Figure 3-3: Differences in DEF values calculated using F6 and F8 tallies. 
 (a) 250 keV photons , (b) 1.00 MeV photons. 
a 
b 
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The results of this simulation are given in Fig. 3-3 above.  It is important to note 
that the width of the peaks shown is an artifact of the plotting routine and is not 
physically relevant.  Plotting additional points in the 4.00 – 4.50 cm and 5.50 – 6.00 cm 
depth ranges would result in a significantly sharper peaks as gold is only present at 
depths of 4.50 – 5.50 cm.  As evident in Fig. 3-3a, using the *F8 tally yields higher 
energy deposition by each tracked photon in the tissue region with implanted gold when 
using 250 keV photons.  However, using 1.00 MeV photons results in the *F8 tally 
drastically underestimating the energy deposition as seen in Fig. 3-3b.  The reason for 
this inconsistency stems from the fact that the F6 tally is an average over all particle 
histories in a given simulation while the *F8 tally records individual events instead of 
averages.  Fluctuations in energy loss rates are not microscopically correlated to account 
for the production of secondary photons.  The target cell may be large enough to smooth 
out these fluctuations for the 250 keV photons, while that is not the case for the 1.00 
MeV photons.  In the absence of microscopically accurate event modeling, the results 
given for the simulations that follow use the F6 tally for all energy deposition 
calculations.  Future work may refine the geometric parameters of the study to such an 
extent that microscopic interactions are simulated accurately.  The *F8 may be used in 
such future work to accurately measure dose deposition. 
 
The following chapters discuss the physical and geometric parameters for each 
model in detail followed by the results that were observed.  All figures shown are not to 
scale and included for ease of reference only.  Detailed geometric figures for the various 
simulations are included in Appendix A.  Sample input files used to for each MCNP5 
simulation are included in Appendix B along with sample output files.  Each case 
included 

1.5105 particles histories and the results that follow are averaged in terms of 
each incident particle.  As a result, while the energy scale given on the figures below is in 
the eV range, the results can be scaled for any beam intensity as the number of photons 
available in a typical photon beam can be varied for specific treatments.  
 47 
Chapter 4 
Preliminary model for gold-mediated effective dose enhancement 
 
 
 The preliminary model was designed to provide a benchmark set of results to 
which various parametric modifications could be compared.  Since the gold 
concentrations levels were maintained at values used in published in vivo studies, the 
quantitatively obtained effective dose enhancement values can be correlated to the 
enhanced survival rates seen in those studies.  In addition, these results should compare 
favorably against other Monte Carlo studies of effective dose enhancement as described 
earlier in Chapter 2.   
 
Given below is a description of each of the simulations run for the preliminary 
model along with a representation of the overall geometric setup used.  The main 
quantitative tools used for comparison are the effective Dose Enhancement Factor 
described in the previous chapter as well as a measure of relative flux.  In order to 
determine the relative intensity of photon flux in the presence of gold, a calculation 
similar to that involving the dose enhancement factor was carried out.  The governing 
equation for these calculations is given below.   
 
 Relative flux


Photon  flux  in  gold bearing  cell
Photon  flux  in  cell  with  no  gold
 (4-1) 
 
 
4.1 Photon energy dependence 
 
The first variable tested was the strength of the beam incident on the side of the 
tissue slab.  The gold concentration in the „tumor‟ slab was kept at a constant 0.7% by 
mass that is consistent with the Hainfeld murine studies that documented a demonstrable 
improvement in treatment when tumor gold concentration was 7 mg per gram of tumor 
tissue (7 mg/g).  As no appreciable cell death was observed in the absence of applied 
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radiation for any of the concentrations used in the Hainfeld study, it is assumed that 
potential cytotoxicity issues are not significant and are ignored for the purposes of this 
work.  Additionally, the location of the „tumor‟ slab was kept at a constant depth of 9 
centimeters.  Although slabs are 2 centimeters thick, the recorded values were plotted at 
the midpoint of the slabs for consistency.  As a result, the target slab was located between 
8 and 10 centimeters away from the beam-incident surface as shown in Fig. 4-1.    
 
 
The results of this simulation were used to bracket the tested beam energy levels 
based on a dose enhancement of at least 1% 

DEF 1.01 .  This was the only filtering 
criterion used at this time and no comment or consideration is given to the clinical 
significance of the resulting range of beam energies.  Discussions of clinical significance 
and application are deferred to the discussion of the more detailed simulations performed.  
Subsequent simulations were designed with more precise spatial and energy parameters 
after reviewing the results of the first preliminary model.  These preliminary results along 
with their relative importance and physical significance are given below.  For the photon 
energy dependence model, the flux (F4) and energy deposition (F6) tallies were recorded 
for photon energies ranging from 100 keV to 2.00 MeV.  While most common 
radiotherapy procedures use photon beams with considerably higher energy levels, as the 
Figure 4-1: Representative geometry for photon energy dependence 
 49 
results that follow demonstrate, the best dose enhancement is seen at lower energy levels 
due to the fact that mass attenuation coefficients for tissue and gold differ significantly in 
that range as discussed earlier and seen in Fig. 1-6.   
 
Mass attenuation coefficients begin to diverge again at photon energies higher 
than 5 MeV, which lends credence to the results reported in the literature using higher 
energy beams.  However, generation of megavoltage beams requires expensive linear 
accelerator systems not found in most hospitals, and so the decision to restrict the energy 
window was motivated by availability of said beams in common hospital settings.  
Alternatively, the characteristic gamma emissions from a Co
60
 source (1.17, 1.33 MeV) 
are easier to obtain and may be available for widespread use.  In order to provide a more 
comprehensive set of energy-dependent results, the range of beam energies was expanded 
to cover the characteristic Co
60
 energies.   
 
 It is important to note that each of the photon sources described in the Monte 
Carlo models that follow is a mono-energetic source.  In practice, photon sources 
generally have a broad energy distribution and this characteristic may be incorporated 
into more detailed models that may follow this work.  However, it is possible to apply 
filters on x-ray machines commonly available in hospitals to generate a photon beam that 
resembles a mono-energetic source.  Further work may be warranted to assess the 
specific effects of filter-reduced photon flux on the results discussed below.   
 
Energy levels for the first simulation were varied from 250 keV to 2.00 MeV with 
an interval step of 250 keV.  An additional 100 keV source was included to better capture 
the effects of using photon energy near the K-edge of gold at 80.7 keV.  Fig. 4-2 plots the 
photon flux profile in the tissue phantom as a function of tissue depth for each of the 
photon energy levels modeled.   
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As seen in Fig. 4-2, the flux drops as a function of depth as would be expected 
due to beam attenuation by the tissue.  Similarly, the changes in attenuation are important 
as they point to the dominant physical mechanisms at work in the slabs of tissue.  The 
flux follows a decay pattern that is consistent for each of the photon energies modeled 
with the magnitude of the decay increases as the photon energy decreases.  Since 
attenuation coefficients follow a similar decay scheme, these results are as expected.   
The distinctly steeper decay for the 100 keV photon beam may be due to the fact that the 
photon beam energy is approaching K-edge of the tissue-gold mixture.  The increase in 
cross section for photoelectric interactions may explain the increase in photon attenuation 
in the tissue phantom. 
 
The changes in attenuation based on the energy of the incident beam can also be 
illustrated using a relative measure as in Fig. 4-3 below.  Here, the flux due to the 
different beam strengths is shown relative to the flux in a tissue sample with no gold – a 
value of 1.00 would represent no change.  For the case of the 100 keV photon beam, the 
relative flux drops drastically in the gold-containing tissue cell – centered on the 9 cm 
mark.  A decrease of 9.1% is seen when comparing the flux before and after the beam 
encounters the tumor gold.  The decrease in relative flux is significantly less pronounced 
for the higher energy beams – the drop over the same span of tissue depths is only about 
2.2% for the 250 keV beam.  As beam energy increases, the drop in relative flux is 
further reduced to less than 1% (when using the 2.00 MeV beam) resulting in a loss of 
utility as far as a dose-enhancement response is concerned.  This loss of utility directly 
corresponds to the fact that mass attenuation coefficients for gold and tissue are virtually 
identical at that photon energy as seen in Appendix D.  Using photon energies higher than 
5 MeV may yield an additional window of utility as attenuation factors for gold and 
tissue begin to diverge at those energy levels.  However, discussion of megavoltage 
photon beams is left for future consideration. 
 52 
 
 
 
 
 
 
 
 
 
 
F
ig
u
re
 4
-3
. R
e
la
ti
v
e
 f
lu
x
 p
ro
fi
le
 f
o
r 
d
if
fe
re
n
t 
in
ci
d
e
n
t 
p
h
o
to
n
 e
n
e
rg
ie
s.
  
A
tt
e
n
u
a
ti
o
n
 d
e
sc
ri
b
e
d
 i
n
 t
e
rm
s 
o
f 
re
la
ti
v
e
 p
h
o
to
n
 f
lu
x
 a
s 
a
 f
u
n
ct
io
n
 o
f 
ti
ss
u
e
 d
e
p
th
 
fo
r 
d
if
fe
re
n
t 
p
h
o
to
n
 e
n
e
rg
ie
s.
 
 53 
Corresponding to the depth-dependent flux attenuation that can be seen in Figs. 4-
2 and 4-3, the energy deposition as a function of tissue depth has an overall negative 
slope as well as seen in Fig. 4-4.  The slope of the energy-depth curve remains relatively 
constant for photon energies higher than 1.00 MeV implying that there is no significant 
improvement in effective dose enhancement.  Meanwhile, sub-MeV energy beams show 
peaks in the energy-depth curve corresponding to an increase in the effective dose 
deposited in the gold-bearing tissue cells.  In order to better highlight this difference, a 
dose enhancement factor was calculated for each energy level using Equation 3-4 and the 
results are plotted in Fig. 4-5.  As can be seen, there is a very significant increase in 
localized energy deposition due to the presence of gold at the tumor site.  DEF values 
ranged from 1.62, for the 100 keV beam, to 1.003, for the 2.00 MeV beam.  These results 
were used to bracket the energy range of further models since MeV photon energies 
resulted in dose enhancement of less than 1% and were determined to be ineffective for 
teletherapy in the scope of this study. 
 
The most significant attenuation was seen for the 100 keV beam since proximity 
to the K-edge of gold results in a photoelectric effect interaction cross section that is 
several orders of magnitude higher compared to the 250 keV beam.  However, the Monte 
Carlo simulations reported by Garnica-Garza showed that photon beam spectra with peak 
energies below 150 keV would result in unacceptably high skin irradiation [72].  As a 
result, the 100 keV beam was not considered in the models that follow.  As mentioned 
above, beam energy higher than 1.00 MeV resulted in dose enhancement of less than 1% 
and so was also not considered for the subsequent models.  While photon energies higher 
than 5 MeV were not simulated in this model, it is conceivable that they would result in 
DEF values higher than 1.00 as discussed earlier.  The scope of this work is limited to 
orthovoltage x-ray beams but future work may consider higher energy levels for 
comparison as well.  Additional consideration is given to potential issues arising from the 
choice of low-energy photon beams in Chapter 6. 
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4.2 Tumor depth dependence 
 
 The second variable tested for possible effects on the DEF was the depth of gold-
laden tumor in the tissue sample.  As discussed earlier, gamma ray interactions in the 
body reach a peak energy deposition and then drop off exponentially.  As a result, the 
depth of the target in the tissue sample should have an effect on the relative improvement 
on the delivered dose.  A shallower target area should result in higher incident photon 
energy and correspondingly result in a lower amount of energy deposition.  Conversely, a 
deeper target area should result in incident photons losing energy in the tissue before 
encountering the target and correspondingly result in a greater energy deposition in the 
target area.  In order to determine what magnitude of improvement could be expected due 
to these factors, the depth of a single tumor slab was defined as 5 cm (A), 9 cm (B), or 15 
cm (C) away from the irradiated surface of the tissue as shown in Fig. 4-6.  Similar to the 
earlier model, the results of this model were used to describe more precise spatial 
geometries for subsequent models. 
 
In order to gain sufficient insight into the effects of tumor depth, the gold-tumor 
slab was placed at the three different depths in the tissue and the flux and energy 
deposition tallies were recorded.  Shown below in Fig. 4-7 a-c, the relative flux profile in 
Figure 4-6: Representative geometry for tumor depth dependence 
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the tissue changed drastically depending on tumor depth.  It is important to note that the 
results shown below are flux measurements relative to the flux with no gold in the tissue 
slab and not absolute measurements.  Also, the data shown in Fig. 4-7e is the same as that 
in Fig. 4-5 with only those beam energies included that fall within the defined filtering 
criteria.   
 
Since the gold slab has a much higher attenuation coefficient than the surrounding 
tissue, it makes sense that the flux should drop off behind the gold.  This is clearly 
evident in each of the depths tested as the relative flux drops below 1.00 in the sections 
sampled after the gold.  It is interesting to note that although each tissue slab experienced 
the same 1% – 3% reduction in relative flux over the entire tissue depth, the decrease 
occurs only after the photon beam encounters the gold.  As a result, the tissue behind the 
gold sees the same reduction in flux, but no beam-gold interaction effects are evident in 
the tissue before the gold.  This profile makes sense since the interaction has not yet 
occurred for those cases, but also means that the benefit of using gold as a radiosensitizer 
is diminished.  The deeper the gold, the larger the volume of tissue that is subject to the 
unmodified photon flux experienced in the absence of gold.  
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Figure 4-7. a-c: Relative flux and DEF for tumor depth dependence.  Flux is plotted as a function of position 
with gold present at depths of 5 cm (a), 9 cm (b), and 15 cm (c). d-f: DEF is plotted as a function of position 
with gold present at depths of 5 cm (d), 9 cm (e), and 15 cm (f). 
a d 
b e 
f c 
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 Although the relative flux profiles look very different depending on the depth of 
the gold in the tissue slab, the distribution shape of the dose enhancement factors 
calculated for each case look relatively similar as seen in Figs. 4-7 d-f.  The obvious 
difference is due to the difference in gold depth, but the overall trend is the same.  A DEF 
of 1.00 is evident in each 250 keV case until the photon beam encounters the gold after 
which there is an increase of more than 16% (1.163 for the 5 cm depth, 1.179 for the 9 
cm depth, and 1.191 for the 15 cm depth).  The increase in the DEF is due to the fact that 
the beam energy decreases as it travels through the tissue, which correspondingly 
increases the photoelectric cross section for the beam.  The DEF increases for the 1.00 
MeV case are significantly less pronounced (1.11, 1.13, and 1.14 respectively) perhaps 
due to the fact that beam does not lose a significant amount of energy in the tissue slab.  
The DEF for each energy level decreases between 2-3% after the photon beam interacts 
with the gold and does not seem dependent on the tissue depth.  Again, this highlights the 
fact that increasing tumor depth results in an increase in the amount of healthy tissue that 
receives a significant radiation dose. 
 
 
4.3 in situ gold concentration dependence 
 
The third variable that was manipulated for the purposes of these preliminary 
models was the concentration of gold at the tumor sites.  Using the Hainfield studies as a 
guide, gold concentrations in the tumor were varied from the initial 7 mg/g up to 30 mg/g 
in the preliminary models.  Both the 7 mg/g and 12 mg/g concentrations were described 
and used in the Hainfield studies that demonstrated the proof-of-concept for dose 
enhancement.  Thus, it was necessary to quantitatively determine the effects of those 
concentrations as described by these models in order to create a reference, to ensure that 
these models were relevant.  The 30 mg/g concentration level was used to show the level 
of enhancement possible using this method with the hope that such a high intra-tumoral 
concentration may be possible in the future.  The geometry used for this iteration of the 
preliminary model is the same as the model which tested photon energy dependence as is 
illustrated in Fig. 4-8.  As mentioned earlier, Chithrani et al. demonstrated markedly 
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higher cellular uptake of 50 nm AuNP compared to nanospheres of smaller diameters.  
As a result, the 7 mg/kg gold concentration has been used here as a benchmark value 
only.  The concentrations in the detailed model take cellular uptake enhancement into 
account.  
 
 
 
 The initial limits for this model were taken from the Hainfeld study that observed 
diagnostically significant improvement with a tumor-gold concentration of 7 mg/g.  A 
maximal limit of 30 mg/g was used to highlight the substantial improvement in tissue 
response to radiation when the gold concentration was increased four-fold.  While this 
upper limit may not be pharmaceutically feasible at the moment, it is conceivable that a 
delivery system may be developed that would be capable of delivering elevated levels of 
gold to tumor sites.  Also, while these gold concentrations are the same as those 
commonly associated with the Hainfeld study, they are used here simply to illustrate the 
effects of tumor-gold concentrations on radiation dose enhancement.  The detailed model 
takes into account the improvements in cellular uptake for larger nanoparticles and the 
tumor-gold concentration is adjusted accordingly.  
Figure 4-8: Representative geometry for in situ gold concentration 
dependence 
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a 
c 
b 
d 
Figure 4-9: DEF for in situ gold concentration dependence.  Graphs shown compare concentrations of 7 mg/kg, 
12 mg/kg and 30 mg/kg for a photon source energy of 0.25 MeV (a), 0.50 MeV (b), 0.75 (c), and 1.00 MeV (d). 
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 The results from this model serve simply to describe the relative effects of in situ 
gold concentrations.  As seen in Figs. 4-9 a-d, increasing the concentration of gold four-
fold from 0.7% (7 mg/g) to 3.0% (30 mg/g) increases the DEF by approximately the 
same factor of four regardless of the source beam energy.  The considerable improvement 
is most evident with 250 keV photons where the DEF increases from 1.18 to 1.66 with a 
corresponding concentration increase.  However, the same relative increase can be seen 
with 1.00 MeV photons where a 1.01 to 1.05 for the same increase in concentration.   
 
 The purpose of this model was to establish a quantitative baseline to which the 
results of the following model could be compared.  Using established in vivo parameters, 
a determination can me made regarding the relative importance of varying different 
details of the model.  These observations gleaned from iterations of the preliminary MC 
model are used to develop the more detailed model that follows.  Improvements in spatial 
geometry, mass-photon interaction considerations, and nanoparticle distribution are all 
taken into account. 
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Chapter 5  
Detailed model for gold-mediated effective dose enhancement 
 
 
As mentioned earlier, the results of the preliminary model were used to define 
more precise geometrical models to be used in a subsequent simulation.    The results of 
the photon energy dependence simulations confirmed an earlier hypothesis that gold 
would be an effective contrast agent when incident photon energy was in the range over 
which the total attenuation coefficients of tissue and gold differed significantly.  Fig. 1-6 
is reprinted here as Fig. 5-1 for ease of reference.  As shown below, the difference in 
attenuation factors is evident in the 5keV – 1 MeV range, which lends credence to the 
decision to restrict incident photon energy to less than 1 MeV.  Additionally, the 
attenuation coefficients begin to diverge at higher photon energies as well, which lends 
insight into the results obtained by Robar et al. as discussed earlier [73].  However, the 
scope of this work is restricted to the sub–1MeV photon beams due to the reasons 
discussed earlier in Chapter 4. 
 
 
 
 
Figure 5-1: Attenuation coefficients for gold and tissue 
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 Similar to the preliminary model, three different cases of the detailed model were 
simulated with the details of each model varying according to one of the conditions 
described below.  Since the effects of gold on photon flux have been illustrated by the 
results of the preliminary model, the results given here focus only on the energy 
deposited in the different volumes.  The corresponding dose enhancement factors are 
calculated as described by Equation 3-5 with the results of each run compared to the 
results with no gold present.  In addition, the results of ideal cases are also presented for 
comparison as described in each of the cases that follow. 
 
 
5.1 Updated in situ gold concentration 
 
 As previously mentioned, Chithrani et al. demonstrated that 50 nm nanoparticles 
have significantly improved cellular uptake compared to the 1.9 nm diameter 
nanospheres used in the Hainfeld study [79].  The Chithrani study reported total gold 
mass internalized by the cells that ranged from 

51012 g to 

91012 g.  By comparing 
the internalized gold mass to the 

3001012 g  average mass of a HeLa cell as reported by 
Popescu et al., in situ concentrations of 1.53% to 2.77% were calculated [85].  A maximal 
gold concentration of 4.00% was also calculated by assuming that the maximum amount 
of internalized gold nanoparticles 

91012 g  occurs in the smallest cells 

2251012 g .  
While such elevated concentrations may prove problematic in healthy cells, it is useful to 
note that the passively targeted AuNP only accumulate at tumor sites via the EPR 
pathway – the prolonged circulation times would ordinarily result in clearance through 
the renal system in the absence of the leaky vessels around a tumor site.  Since gold 
uptake is dependent on nanoparticle interactions with the cell membrane, this 
concentration is unlikely to occur in normal physiological settings using currently 
available pharmaceutical techniques, but is taken here to represent the maximum 
concentration of gold that could conceivably be achieved in future clinical settings.  The 
updated model is represented in Fig. 5-2. 
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 As can be expected, the results of the updated gold concentration model in Fig. 5-
3 illustrate the benefit of using the maximum possible gold at the tumor site.  
Additionally, the lower photon energies display significantly greater propensity for dose 
enhancement due to the incidence of photoelectric interactions.  The physiologically 
achievable concentration of 2.77% resulted in a dose enhancement factor of 1.54 
compared to 1.19 calculated using the 1.2% concentration reported by Hainfeld.  The 
gradual decrease in DEF values within the tumor volume may be due to the inherent 
shielding that occurs due to the gold particles distributed in the tumor volume as 
discussed in Chapter 4.  Since the gold is modeled as a homogenous mixture, the density 
of the tumor is significantly higher than the surrounding tissue, which may also 
contribute to this shielding effect.  The conclusions drawn from the results of the 
preliminary model all apply to this iteration of the detailed model as well, with the 
notable exception being the improvement in dose enhancement even at higher photon 
energies and lower gold concentrations.  Additionally, the upper limit for dose 
enhancement is raised to 76% with a gold concentration of 4.00% corresponding to 40 
mg of gold per gram of tumor tissue. 
 
 
Figure 5-2: Updated gold concentration and dimensions for detailed 
model 
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5.2 Lack of nanoparticle specificity 
 
 Despite the convenience of EPR effects present at tumor sites, passive 
nanoparticle targeting is not perfect.  The use of monoclonal antibodies and other tumor-
specific markers can be used to improve the specificity with which the nanoparticles 
target the preferred site, but these techniques have not been used in radio-sensitivity 
studies this far.  As a result, a certain degree of diffusivity must be accounted for when 
modeling the distribution of gold around a tumor site.  The study by Hainfeld et al. 
described passive tumor targeting and diffusion was observed when the excised murine 
tissue was analyzed for gold content [76].  Tumor to tissue concentration rations ranging 
from 8.5:1 to 3.5:1 were observed in the mice treated with 1.9 nm nanoparticles.  Since 
this work is assuming a particle diameter of 50 nm due to improved cellular uptake 
characteristics, it is possible that the diffusion ratio may approach the lower end of the 
range observed by Hainfeld. 
 
 In order to model the effects on effective dose enhancement due to possible 
nanoparticle diffusion, a concentration of gold was distributed in the tissue immediately 
outside the simulated tumor.  The tissue cells, immediately outside the tumor, were split 
in half with the diffusing nanoparticles in the half closer to tumor.  All other geometric 
Figure 5-4: Representative geometry for gold specificity dependence.   
Passive diffusion results in lower concentration proximal to tumor 
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details were left unchanged from the previous simulation.  Fig. 5-4 illustrates the 
geometric distribution of the gold-bearing volumes; the overall geometry is assumed to 
be the same as that described in Fig. 3-2. 
 
In order to get a lower bound on enhancement (the worst case scenario), the 
lowest in situ gold concentration of 1.53% was defined in the tumor region and a tumor 
to tissue ratio of 3.5:1 was used to yield a concentration of 0.44% in the immediately 
adjacent tissue.  This was contrasted with a tumor to tissue ratio of 8.5:1 yielding a 0.18% 
gold concentration in the surrounding tissue.  Both results then compared against the 
ideal tumor-targeting scenario with no diffusion of the gold into the surrounding healthy 
tissue.  The results below show the effects of no diffusion, a diffusion ratio of 8.5:1, and a 
diffusion ratio of 3.5:1 with beam energies ranging from 250 keV to 1.00 MeV.  Dose 
enhancement factors are plotted as a function of tumor depth in Fig. 5-5, and the results 
are focused on the tissue volumes immediately surrounding the tumor.  As a result, DEF 
values are only given at depths ranging from 3.00 cm to 7.00 cm as the values for tissue 
depths outside that range are unchanged from the previous simulation. 
 
 As can be expected, the DEF profiles for each set of results is less discrete around 
the tumor site due to the presence of gold outside the tumor volume.  While the 
maximum values for DEF are unchanged for all photon energies, the decrease in effective 
dose after the photon beam passes through the tumor volume is of interest.  Since it is 
unlikely that gold nanoparticles would be distributed homogenously outside the tumor, it 
may be possible to shape the external beam geometry to reduce effective dose around the 
tumor.  If the beam is shaped in such a way that the excess gold outside the tumor is 
targeted before the tumor volume, rather than after, the photons arriving at the tumor site 
with have lost a portion of their energy before entering the tumor volume.  As a result, 
the gold-laden tumor will have a higher sensitivity to the photon beam due to the energy-
dependence discussed above.  This explanation may account for the sharper decrease in 
DEF values for both cases where gold is present outside the tumor volume as seen at the 
6.00 cm to 7.00 cm depth in Figs. 5-5 (b), (c), and (d) below. 
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5.3 Non-homogeneous gold distribution 
 
 Each of the in vivo studies reviewed discussed the possibility that treating the gold 
nanoparticles as a homogenous tissue-gold mixture would result in a misrepresentation of 
the dose enhancement calculated in Monte Carlo simulations.  As a result, a non-
homogenous gold distribution was defined in the tumor slab based on the assumption that 
the gold nanoparticles would not be able to penetrate into the center of the tumor.  The 
ensuing aggregation at the periphery of the tumor is defined as having the same updated 
gold concentration as the previous model described above.  However, since EPR effects 
may not extend to the center of a tumor, the amount of gold at the center is reduced to a 
lower concentration at the edges of the tumor.  This non-homogeneity is illustrated in Fig. 
5-6 and the overall geometry is again assumed to be the same as described in Fig. 3-2. 
 
 
 As mentioned, several studies discussed the potential issues with assuming 
homogeneously distributed gold nanoparticles throughout a tumor volume.  In order to 
gain some insight into the effects of non-homogeneity, several simulations were 
performed under the assumption that gold nanoparticles may not fully penetrate a tumor 
volume.  The gold concentrations from the Chithrani study were used to generate a 
baseline DEF curve with the assumption that the tumor gold distribution was 
Figure 5-6: Representative geometry for homogeneity dependence.  
Lower concentration at center of tumor due to lack of Au penetration. 
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homogenous.  Since in vivo tumor penetration studies have not been done to the author‟s 
knowledge, the reduction factors for the center of the tumor were taken from work 
described by Hainfeld et al. where passive nanoparticle diffusion was observed [76].  
Although this iteration of the model does not account for diffusion into healthy cells, 
similar physical interactions are assumed to allow gold to reach the center of the targeted 
tumor.  As with the specificity-dependence model described above, ratios of 8.5:1 and 
3.5:1 were used to ascribe the gold concentration levels to the different tumor regions.  
Results are compared against the ideal scenario with homogeneously distributed gold 
throughout the tumor region. 
 
It is argued above that the larger diameter nanoparticles used in this work may 
result in passive diffusion into untargeted healthy cells.  Although the mechanism of 
transport for passive diffusion outside the tumor and nanoparticle penetration into the 
tumor will differ, the assumption is that the enhanced influx of 50 nm nanoparticles 
extends beyond the tumor periphery.  However, in the absence of in vivo studies for 
corroboration, the results of this simulation may only provide a rough approximation of 
the quantitative effects of gold nanoparticles accumulating in the tumor periphery without 
penetrating to the core of the tumor volume. 
 
 Given below is a set of results obtained by assuming periphery to core ratios of 
3.5:1 and 8.5:1 with four different photon energies and at 1.53% baseline gold 
concentration.  Additionally, results from simulations using 250 keV and 1.00 MeV 
photons along with a 2.77% baseline gold concentration are included to demonstrate the 
similarity in DEF profiles, as only the amplitude is different.  These plots are followed by 
a series of results obtained by combining different nanoparticle penetration ratios and 
passive nanoparticle diffusion outside the tumor volume.   
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Figure 5-7: DEF profiles for homogeneity dependence.  Variations within a tumor volume are shown for (a) 
250 keV, (b) 500 keV, (c) 750 keV, and (d) 1.00 MeV photons.  Baseline [Au] is defined as 1.53% by mass.  Also 
included: DEF variations using baseline [Au] of 2.77% for (e) 250 keV and (f) 1.00 MeV photons. 
a b 
c d 
e f 
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 The results plotted in Fig. 5-7 illustrate the effects of having a lower concentration 
of gold at the center of the tumor compared to the tumor periphery.  As expected, the 
effective dose enhancement due to the presence of gold is reduced in the areas with lower 
gold concentrations.  Additionally, the lack of gold results in the photon beam retaining 
more energy as it passes through the tumor due to the lack of high-Z material.  This 
results in a second peak in the DEF curve when the beam interacts with the distant tumor 
boundary.  This also accounts for the fact that the 1.00 MeV photon beam deposits more 
energy at the distant tumor boundary in the case with non-homogeneous gold 
distribution.  However, averaged over the whole tumor volume, the dose enhancement is 
reduced as expected for the non-homogeneous case.  The results of running the 
simulation with a baseline gold concentration of 2.77% are also included for photon 
energies of 250 keV and 1.00 MeV.  Comparing these results to those for the lower gold 
concentration, it is easy to see that the DEF profiles are identical in variation.  The 
difference arises in the amplitude of the curves as the higher gold concentration naturally 
results in a higher overall level of dose enhancement.  Consequently, the results of the 
[Au]=1.53% simulation may be extended for any physiologically realistic gold 
concentration with similar DEF variations. 
 
 A worst-case scenario was also simulated where no gold nanoparticles penetrate 
to the center of the tumor volume.  In this case, a 250 keV photon beam was incident on a 
tissue phantom with the same geometrical parameters as the previous study testing 
homogeneity dependence.  In addition to the lack of gold transport to the tumor core, it 
was also assumed that non-specific uptake of the gold nanoparticles into the healthy 
tissue surrounding the tumor volume would occur.  This case, as described, may represent 
a tumor atypically resistant to particle transport combined with a poorly designed tumor-
targeting scheme.  The results for this case are given in Fig. 5-8. 
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Significant dose enhancement was observed in the gold-bearing volumes with 
DEF values approaching 1.30 for both tumor periphery cells.  However, the results 
suggest that no additional dose would be deposited at the tumor core.  Contrasted to the 
DEF values of unity at the tumor core, the passive diffusion modeled outside the tumor 
resulted in excess doses of 4% and 9% for the diffusion ratios tested (tumor to tissue 
ratios of 8.5:1 and 3.5:1 respectively).  While more detailed models are needed, both at 
the macroscopic and microscopic levels, before any conclusive statements can be made, it 
is clear that tumor penetration may be a significant obstacle that must be overcome for 
successful and effective radiation treatments. 
 
Given these results, it is important to note that none of the simulations take into 
account active targeting strategies, and that all gold is assumed to accumulate and diffuse 
through passive transport.  The maximum limit on gold concentrations in tumor cells 
used in these simulations is based on published in vivo studies using unmodified gold 
nanoparticles.  The specific concentration of intracellular gold possible using monoclonal 
antibody tagging has not been well established.  Needless to say, implementing specific 
targeting strategies that incorporate the cell surface markers unique to tumor cells should 
result in improved effective dose enhancement.   
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Chapter 6 
Analysis and Conclusions 
 
 
Presented here is what aims to be a detailed look at the possibilities and benefits 
of using gold in teletherapy radiation treatment models.  The results from various Monte 
Carlo simulations are discussed with special attention given to the radio-sensitivity 
dependence on photon energy, gold nanoparticle concentration, tumor depth, targeting 
specificity, and nanoparticle penetration.  The result of the preliminary model are 
presented to quantitatively corroborate published in vivo and in vitro studies and expand 
the amount of analytical data available to direct future work.  Additionally, the results of 
the detailed model attempt to predict some of the limitations and restrictions inherent in 
the application of unmodified gold nanoparticles for radio-sensitivity.  The hope is that 
the effect of the relevant physical mechanisms described here may guide the development 
of enhanced targeting mechanisms and inspire future work. 
 
6.1 Discussion of results 
 
Based on the results obtained from the preliminary model, it is clear that the 
physiological response observed in Hainfeld studies was due to the effective dose 
enhancement observed at the tumor sites.  The original study used 68 keV and 157 keV 
photon beams and reported that the lower energy photons showed improved tumor 
eliminating efficacy.  While the work here did not address those specific energy levels, 
the energy-dependent preliminary model was designed to develop an understanding of 
the overall energy-dependence of effective dose enhancement.  Using the 7 mg/kg gold 
concentration reported by Hainfeld, DEF values of over 1.60 were observed when using a 
100 keV photon beam.  The effective dose enhancement dropped to 1.18 using a 250 keV 
photon beam and 1.05 when photon energy was increased to 500 keV.  The DEF values 
monotonically decreased as photon energy was increased and a minimum DEF of 1.003 
was obtained using a 2.00 MeV photon beam.  Given these results, it is easy to see that 
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decreasing the photon beam energy improves the effective dose enhancement at the 
tumor site. 
 
Analyzing the results of the first simulation leads to the idea that the lowest 
possible energy should be used for tumor targeting.  However, one of the primary 
concerns when reducing photon energy is the reduction in the penetrating ability of the 
photon beam.  Although the lower energy photons have a higher interaction cross-section 
for the gold-laden tumor, the interaction cross sections of healthy tissue are not exempt 
from a similar increase.  This property is illustrated in the depth-dependence preliminary 
model.  The goal of this simulation was to determine whether reducing the photon beam 
energy would result in a reduction in energy deposition due to premature attenuation of 
the photon beam.  The results showed that DEF had a relative lack of dependence on the 
depth of the tumor and doubling the tumor depth only changed the effective dose 
enhancement by a maximum of 3%.  These results were also observed in the 100 keV 
photon case as shown in Fig. 6-1, which would lead to the conclusion that the low energy 
photons should be the ideal candidate for this work.  However, the energy deposited per 
photon in the 100 keV case is less than 10 eV per gram of tumor tissue and the intensity 
of the photon beam required to deliver a lethal dose of radiation to the tumor volume 
would result in unacceptably large doses to surface tissues.  This result agrees with the 
Garnica-Garza study discussed earlier, and as a result, the 100 keV photons were not 
included in further simulations [72]. 
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Finally, the last preliminary model was designed to test the effects of the in situ 
gold concentration on effective dose enhancement.  The results here were largely as 
expected as the amount of gold at a tumor site should effectively increase the density of 
the target volume.  In addition, an increase in the number of electrons in the target 
volume as a result of the increased gold concentration should improve the photoelectric 
cross section of the tumor.  These improvements can be clearly seen as increasing the 
gold concentration from 7 mg/kg to 30 mg/kg led to a more than three-fold increase in the 
effective dose enhancement.  The DEF increased from 1.18, when a 250 keV photon 
beam was used to irradiate a 7 mg/kg concentration of gold, to 1.66 when the same 
photon beam was used to irradiate the 30 mg/kg gold concentration.  These results clearly 
indicate that radiation sensitivity is directly proportional to the amount of gold that can be 
accumulated at the tumor site.   
 
The first detailed model expanded on the results of the concentration-dependent 
preliminary model by incorporating the results of the Chithrani study using larger 
diameter gold nanoparticles.  Increasing the particle diameter from 1.9 nm to 50 nm 
resulted in increased in situ gold concentrations with the upper bound of the average gold 
concentration (27.7 mg/kg) approaching the 30 mg/kg concentration previously thought 
to be clinically infeasible.  The maximum potentially achievable concentration was 
subsequently calculated to be 40 mg/kg using the larger nanoparticles.  Using the higher 
gold concentrations yielded improved effective dose enhancements, which were 
significantly larger that those previously observed in the preliminary model.  Using a 250 
keV photon beam, the improved gold concentration yielded a DEF of 1.26 using the 15.3 
mg/kg gold concentration (lower bound), and a DEF of 1.76 for the 40.0 mg/kg gold 
concentration (maximum concentration).  In clinical terms, a DEF of 2.0 would imply 
that the presence of gold would effectively half the intensity of the photon beam required 
to treat a tumor when compared to the same treatment in the absence of gold.  The results 
of the updated concentration model, therefore, suggest that maximizing the tumor gold 
concentration will significantly improve tumor treatment. 
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The next two simulations were conducted to determine the effect of localized non-
homogeneities and inconsistencies in an attempt to approximate clinical realism.  In an 
ideal scenario, the gold prescribed to a tumor patient would accumulate locally and 
exclusively at the tumor site.  This would then result in sharp peaks in the effective dose 
enhancement profiles as seen in the previous simulations described here.  However, 
realistically modeling of gold nanoparticle distribution in the body must account for 
passive uptake into the healthy cells surrounding the tumor tissue since the nanoparticles 
are not specifically targeted.  As previously discussed, this non-specificity may be 
minimized or avoided completely if successful tagging using monoclonal antibodies can 
be achieved.  The in vivo and in vitro studies reviewed, however, do not discuss the use 
of such active targeting strategies and consequently, retain the issues associated with non-
specific targeting.  As such, in order to retain the ability to corroborate the data obtained 
from the simulations presented here, a more realistic distribution of gold was modeled in 
and around the tumor site using passive nanoparticle transport mechanisms. 
 
As mentioned, one of the issues that arise with non-specific targeting is passive 
uptake in the healthy cells around the tumor site.  In order to model this, a concentration 
gradient was established across the boundary of the tumor volume.  A tumor cell to 
healthy cell concentration ratio was defined based on the data reported by the Hainfeld 
study concerning gold concentrations.  The results of two such ratios (3.5:1 and 8.5:1) 
were compared to the ideal targeting scenario to determine the relative effects of passive 
targeting.  As expected, the effective dose in the gold-laden healthy tissue was about one-
third and one-eighth the effective dose in the gold-laden tumor volume respectively.  In 
addition, the DEF values for photon interactions in the healthy tissue after the tumor 
volume were lower when gold was present outside the tumor boundary.  This may be 
attributable to the fact that the photons had lost a considerable portion of their energy in 
the broader gold-laden region.  If accurate imaging can be performed on the tumor 
volume to determine the real-time distribution of the gold nanoparticles, this asymmetry 
in the effective dose deposition may be utilized to minimize dose to healthy cells. 
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Another issue that arises when quantifying nanoparticle distribution is the fact 
that a mechanism for tumor volume penetration has not been identified.  As a result, even 
if active targeting strategies are used to ensure accumulation of gold at the tumor site, 
there is no mechanism currently discussed in the literature that would ensure a 
homogeneous distribution of gold in the tumor volume.  In order to take this problem into 
account, the distribution-dependent simulation was run with the assumption that some 
non-ideal tumor penetration may take place.  Since no specific values have been reported 
for in vivo studies, a conservative estimate was made using the same diffusion ratios used 
for the non-specificity simulation discussed above.  In addition, a worst-case scenario 
was also modeled to describe the effective dose enhancement profile for the case where 
no gold is able to penetrate the tumor volume. 
 
The results of this simulation were largely as expected.  The lack of gold at the 
center of the tumor volume resulted in a bi-peaked effective dose enhancement profile.  
The DEF values for the tumor core were similar to those observed for the healthy tissue 
boundary in the diffusion-dependent case.  In the ideal tumor penetration case, effective 
dose enhancement decreases with increasing tumor depth.  In the case with no gold in the 
tumor core, the amplitude of second peak in the DEF profile was larger than the 
amplitude of the monotonically decreasing profile in the ideal case.  This may be due to 
the fact that the homogeneous gold distribution may induce more scattering events and 
allow fewer photons to penetrate the tumor volume.  The non-homogeneous gold 
distribution may not induce as many scattering events so a larger number of photons may 
reach greater depths in the tumor. 
 
 
6.2 Relevance to other clinical applications 
 
 Since no treatment modality has yet been developed to ideally treat tumor masses, 
the work here attempts to elucidate the variables that may be manipulated in order to 
achieve the greatest level of efficacy using current radiotherapy treatments.  The use of 
nano-scale gold is becoming increasingly common in pharmaceutical applications, so the 
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assumption that it may be used to develop an effective radio-sensitizing contrast agent is 
easily valid.  Furthermore, the geometric considerations discussed in this work can be 
manipulated to present an improved effective geometry in clinical settings.  Choosing 
appropriate beam angles can allow for effective control of the tumor depth.  While this 
may not be possible for deep-seated, soft tissue tumors, sub-surface and asymmetrical 
tumor locations may be candidates for such depth variance.  Additionally, implementing 
both active and passive targeting strategies can allow for precise control of the in situ 
concentration of the gold nanoparticles. 
 
It must be said that the idea of effective dose enhancement is not limited to 
radiation therapy using only photons.  Boron Neutron Capture Therapy (BNCT) uses 
boron as a contrast agent for neutron therapy as its absorption cross-section is 
significantly higher than the corresponding cross section for tissue.  A linear accelerator 
or nuclear reactor is used to produce neutrons that are then shaped into a useful beam 
using various moderators and collimators.  As the beam travels through the patient, the 
neutrons are attenuated and become thermal.  These neutrons are then absorbed by B
10
 
that subsequently decays to produce Li
7
 and He
4
.  These ions produce significant 
ionization locally surrounding the interaction site.  This method to produce localized 
effective dose can be compared to the effective dose enhancement described in this work 
here.  However, BNCT has not been shown to significantly improve upon the current 
radiation therapies and so has not entered widespread clinical use.  The difficulties in 
obtaining the neutron beams contribute to the delay in the acceptance of BNCT as a 
clinical therapy modality as the results are not improved to a level where the capital and 
logistic investments are feasible.  As a result, using contrast media to achieve effective 
dose enhancement as described here is significantly more promising in existing photon 
therapy applications than in neutron therapy applications. 
 
 Although the work described here uses gold as the basis for radio-sensitizing 
contrast agents, several other candidates may be evaluated in the future.  Both iodine and 
gadolinium have been studied in the past and shown relative success.  However, a more 
promising candidate for further research may be platinum.  Since its atomic number (78) 
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is very similar to that of gold (79), the electron density-dependent interactions 
mechanisms should be relatively identical.  In addition, several organoplatinum 
compounds are currently under investigation for use in chemotherapeutic applications.  
Cisplatin, approved by the FDA since 1978, and its analogs have a platinum core, which 
may prove sufficient for radio-sensitizing applications once the drug is administered.  
These drugs affect cell death by inducing DNA cross-linking reactions in tumor cells.  If 
drug administration is followed by radiation doses, the drug may act as the contrast agent 
necessary for effective dose enhancement.  While cytotoxicity issues limit the 
concentrations that may be achieved in vivo, it is conceivable that effective dose 
enhancement might be seen even at low doses. 
 
 
6.3 Recommendations for future work 
 
 The broadest assumption made in the development of this work is that the contrast 
material distributes itself homogeneously in the target volume.  While this assumption 
yields results that are sufficient to explain the overall interaction mechanisms and the 
major geometric variables, more detailed modeling is necessary to achieve clinically 
sufficient accuracy.  There are several ways the results of this work may be extended to 
provide additional clinical relevance as described below. 
 
Ideally, this work will be followed up by a microscopic treatment of the gold 
nanoparticles in the tissue sample to accurately model the specific photoelectric 
interactions that occur in the tumor volume.  Designing and simulating a microscopically 
detailed model may prove to be very computationally expensive but may be 
accomplished by utilizing the computing power of one of several computing clusters 
currently available.  Additionally, the models described here may need to be modified for 
Monte Carlo codes that do not use the condensed particle history approach to particle 
transport utilized by MCNP5.  A detailed transport approach may more accurately predict 
where particle energy will be deposited in these simulations.  Additionally, modeling the 
photon beam to include an energy spectrum may produce large improvements in effective 
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dose enhancement as compared to using mono-energetic photon beams due to the strong 
dependence on photon energy.  Investigating the use of active targeting strategies such as 
monoclonal antibodies may also yield improved effective dose enhancement, as the 
amount of gold that reaches a tumor site may be significantly higher. 
 
It is also worth mentioning that while this study acknowledges the limitations on 
the minimum photon energy that would be clinically feasible, a relative benefit analysis is 
not included here.  A logical next step from this work would be to determine accurate 
dose profiles resulting from low-energy photon beams interacting with healthy tissue.  
The use of tissue phantoms in an experimental setting may be used to quantify these 
profiles.  Alternatively, a microscopically detailed MC analysis of surface and shallow 
tissue depths may be warranted to validate the choice of sub-MeV photon beams in the 
models described here.  The results of these dose profile studies may then be used to 
compare the effective dose enhancement obtained using nano-scale gold to the increased 
effective dose deposited in surface tissues due to lower photon energies. 
 
 These potential improvements notwithstanding, it is the author‟s opinion that the 
work presented here improves on the amount of data available to aid in the design of 
future in vivo investigations and is sufficient to motivate increased investigation into the 
uses of gold as a radio-sensitizing contrast agent. 
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APPENDIX A  
Detailed geometries for MC models 
 
 Given here are detailed representations of the geometries used in the input 
files that follow.  Although an attempt has been made to accurately scale the tissue 
volume, the distance between the source plane and the tissue volume is not drawn 
to scale.  The distance between the source plane and the tissue volume is kept 
constant at 2 cm in all models and has been omitted from these diagrams purely for 
the sake of clarity to avoid obscuring the detailed rendering of the tissue volume.   
 
Fig. A-1 below describes the overall geometry for the preliminary model with 
overall dimensions of 20 cm by 20 cm by 20 cm.  The slabs are 2 cm thick 
throughout the tissue volume, and the tumor slab designation depends on the 
specific model being run.   
 
Fig. A-2 below describes the overall geometry for the detailed model with 
overall dimensions of 10 cm by 10 cm by 10 cm.  The slabs throughout the volume 
are 1 cm thick, and the tumor slab is further divided into 0.25 cm slices.  For the 
detailed model, the tumor slab was kept at a constant depth of 4.5 cm, and a 0.5 cm 
skin layer was also modeled. 
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APPENDIX B 
Sample input and output files from MCNP5 simulations 
 
 
Given below are sample input files for the simulations run in this work.  One input file is 
included for each model with the relevant variables marked in bold. 
 
Preliminary model – Sample input: 
 
c Gamma ray beam source with Au 
c  
c Input simulates gamma ray source 2 cm left of origin 
c Gamma ray source strength = 0.10 MeV [Varied for source dependence] 
c Au concentration in tissue = 0.7%  [Varied for concentration dependence] 
c Tumor depth in tissue = 5 cm [Varied for depth dependence] 
c Last edited on: Wednesday, February 2, 2011 
c 
c ----------------------  Cells, regions definition --------------------------- 
c The source is assumed to be planar, aimed at the left edge of the tissue 
c The cells are defined as inside the boundary box and left/right of  
c the different y-planes slicing through at 2 cm intervals. 
c Density: Healthy tissue    m1 =  1.07 g/cm3 
c          Tumor with Au     m2 =  1.1977 g/cm3 
c  
   1  0           -1  -2      $ Vacuum behind source plane 
   2  0           -1   2  -3  $ Source on the left edge of cell 
   3  1  -1.07    -1   3  -4  $ Healthy tissue 
   4  1  -1.07    -1   4  -5  $ Healthy tissue 
   5  1  -1.07    -1   5  -6  $ Healthy tissue 
   6  1  -1.07    -1   6  -7  $ Healthy tissue 
   7  2  -1.1977  -1   7  -8  $ Tumor with 0.70% Au 
   8  1  -1.07    -1   8  -9  $ Healthy tissue 
   9  1  -1.07    -1   9  -10 $ Healthy tissue 
  10  1  -1.07    -1  10  -11 $ Healthy tissue 
  11  1  -1.07    -1  11  -12 $ Healthy tissue 
  12  1  -1.07    -1  12      $ Healthy tissue 
  13  0           1           $ Vacuum outside problem boundary [outside box] 
 
c ----------------------       Surfaces / Bodies    ---------------------- 
  1  RPP  -10 10  -2.001 20  -10 10  $ Box macro-body, L=W=H=20 
  2  py  -2.0                        $ Surface plane                            
  3  py   0.0                        $ Slices in the y-plane                    
  4  py   2.0                        $                                          
  5  py   4.0                        $                                          
  6  py   6.0                        $                                          
  7  py   8.0                        $                                          
  8  py  10.0                        $                                          
  9  py  12.0                        $                                          
 10  py  14.0                        $                                          
 11  py  16.0                        $                                          
 12  py  18.0                        $          
 
c ----------------------     Problem definition     ---------------------- 
 95 
c        1 2 3 4 5 6 7 8 9 0 1 2 3    $ Cell numbering 
  imp:p  0 1 1 1 1 1 1 1 1 1 1 1 0    $ photons disappear at boundary 
  mode p                              $ Photon transport (no secondary e) 
  nps 150000                          $ Number of histories 
c 
c ----------------------    Source definition     ------------------------ 
  sdef par = 2            $ Photon source 
       erg = 0.10         $ Energy level [MeV] 
       sur = 2            $ Source points sampled over surface 2 at y = -2 
       vec = 0 1 0        $ Reference vector (Source in +y direction) 
       dir = 1            $ Cos of angle between vec and beam vector 
       pos = 0 -2 0       $ Center of sampling range (0,-2,0) 
       rad = d1           $ Beam width distribution 
  SI1 0 10                $ Source sampled over r=0 to r=10 
  SP1 -21 1               $ Power rule with a=1 (Constant sampling) 
c 
c ----------------------    Response functions    ------------------------ 
  f14:p   3 4 5 6 7 8 9 10 11 12   $ Average p flux in cells 3-12 [num/cm2] 
  f16:p   3 4 5 6 7 8 9 10 11 12   $ Energy deposition in  3-12 [MeV/g] 
c 
c ----------------------    Materials             ------------------------ 
c Composition of bodily materials                                                      
c 
  m1    1000.04p       -0.1020         $ Healthy tissue 
        6000.04p       -0.1430 
        7000.04p       -0.0340 
        8000.04p       -0.7100 
       11000.04p       -0.0010 
       15000.04p       -0.0020 
       16000.04p       -0.0030 
       17000.04p       -0.0010 
       19000.04p       -0.0040 
c 
  m2    1000.04p       -0.1013        $ "Tumor" layer with diffused Au 
        6000.04p       -0.1420 
        7000.04p       -0.0337 
        8000.04p       -0.7050 
       11000.04p       -0.0010 
       15000.04p       -0.0020 
       16000.04p       -0.0030 
       17000.04p       -0.0010 
       19000.04p       -0.0040 
       79000.04p       -0.0070        $ 0.70 % mass fraction of gold 
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Detailed model – Sample input file: 
 
c Gamma ray beam source with Au in tumor and diffusion around the tumor site. 
c Cells directly adjacent to tumor have a ___:1 tumor:tissue ratio for Au 
c diffusion.  [Varied for specificity dependence] 
c  
c Input simulates gamma ray source 2 cm left of origin 
c Gamma ray source strength = 0.25 MeV 
c Au concentration in tissue = -- [Varied for concentration dependence] 
c Last edited on: Monday, February 21, 2011 
c 
c ----------------------  Cells, regions definition --------------------------- 
c The source is assumed to be planar, aimed at the left edge of the tissue. 
c Target cells are defined as 1 cm slabs orthogonal to the source plane.  Tumor 
c is defined as a 1 cm thick slab at a depth of 4.50 cm. 
c  
c Density: Skin tissue               m1 =  1.09   g/cm3 [ICRU 46] 
c          Healthy tissue            m2 =  1.0700 g/cm3 
c 
c          "Tumor" with 0.70% Au     m3 =  1.3491 g/cm3 
c          Tissue with 3.5:1 ratio   m4 =  1.1497 g/cm3 
c          Tissue with 8.5:1 ratio   m5 =  1.1028 g/cm3 
c 
c          "Tumor" with 1.20% Au     m6 =  1.5752 g/cm3 
c          Tissue with 3.5:1 ratio   m7 =  1.2144 g/cm3 
c          Tissue with 8.5:1 ratio   m8 =  1.1294 g/cm3 
c 
c          "Tumor" with 3.000% Au    m9 =  1.7996 g/cm3 
c          Tissue with 3.5:1 ratio   m10=  1.2785 g/cm3 
c          Tissue with 8.5:1 ratio   m11=  1.1558 g/cm3 
c  
   1  0          -1  -2      $ Vacuum behind source plane 
   2  0          -1   2  -3  $ Source on the left edge of cell 
   3  1  -1.09   -1   3  -4  $ Skin layer 
   4  2  -1.07   -1   4  -5  $ Healthy tissue 
   5  2  -1.07   -1   5  -6  $ Healthy tissue 
   6  2  -1.07   -1   6  -7  $ Healthy tissue 
   7  2  -1.07   -1   7  -8  $ Healthy tissue 
   8  2  -1.07   -1   8  -9  $ Tumor tissue [Concentration reduced 
   9  2  -1.07   -1   9  -10 $ Tumor tissue  in center to account for 
  10  2  -1.07   -1  10  -11 $ Tumor tissue  penetration dependence] 
  11  2  -1.07   -1  11  -12 $ Tumor tissue 
  12  2  -1.07   -1  12  -13 $ Healthy tissue 
  13  2  -1.07   -1  13  -14 $ Healthy tissue 
  14  2  -1.07   -1  14  -15 $ Healthy tissue 
  15  2  -1.07   -1  15  -16 $ Healthy tissue 
  16  2  -1.07   -1  16      $ Healthy tissue 
  17  0          1           $ Vacuum outside problem boundary [outside box] 
 
c ----------------------       Surfaces / Bodies    ---------------------- 
  1  RPP -5.0 5.0  -2.001 10.0  -5.0 5.0  $ Box macro-body, L=W=H=20 
  2  py  -2.0                             $ Surface plane                            
  3  py   0.0                             $ Slices in the y-plane                    
  4  py   0.5                             $                                          
  5  py   1.5                             $                                          
  6  py   2.5                             $                                          
  7  py   3.5                             $                                          
  8  py   4.5                             $                                          
  9  py   4.75                            $ Tumor sliced into four 0.25 cm 
 10  py   5.00                            $ slabs for better spatial resolution 
 11  py   5.25                            $                                         
 108 
 12  py   5.50                            $                                          
 13  py   6.5                             $          
 14  py   7.5                             $          
 15  py   8.5                             $          
 16  py   9.5                             $          
 
c ----------------------     Problem definition     --------------------------- 
c         1 2 3 4 5 6 7 8 9 0              $ Cell numbering 
  imp:p,e 0 1 1 1 1 1 1 1 1 1 & 
          1 1 1 1 1 1 0                    $ Photons disappear at boundary 
  mode p e                                 $ Photon transport 
  nps 150000                               $ Number of histories 
c 
c ----------------------    Source definition     ----------------------------- 
  sdef par = 2            $ Photon source 
       erg = 0.25         $ Energy level [MeV] 
       sur = 2            $ Source points sampled over surface 2 at y = -2 
       vec = 0 1 0        $ Reference vector (Source in +y direction) 
       dir = 1            $ Cos of angle between vec and beam vector 
       pos = 0 -2 0       $ Center of sampling range (0,-2,0) 
       rad = d1           $ Beam width distribution 
  SI1 0 5                 $ Source sampled over r=0 to r=5 
  SP1 -21 1               $ Power rule with a=1 (Constant sampling) 
c 
c ----------------------    Response functions    ----------------------------- 
  f6:p   3 4 5 6 7 8 9 10 11 12 13 14 15 16     $ Heating number approx. 
[MeV/g] 
  *f8:p  3 4 5 6 7 8 9 10 11 12 13 14 15 16     $ Modified pulse height  [MeV]  
c 
c ----------------------    Materials             ----------------------------- 
c Composition of bodily materials 
c 
c Skin tissue 
  m1    1000.04p       -0.100 
        6000.04p       -0.204 
        7000.04p       -0.042 
        8000.04p       -0.645 
       11000.04p       -0.002 
       15000.04p       -0.001 
       16000.04p       -0.002 
       17000.04p       -0.003 
       19000.04p       -0.001 
c 
c Healthy tissue 
  m2    1000.04p       -0.1020 
        6000.04p       -0.1430 
        7000.04p       -0.0340 
        8000.04p       -0.7100 
       11000.04p       -0.0010 
       15000.04p       -0.0020 
       16000.04p       -0.0030 
       17000.04p       -0.0010 
       19000.04p       -0.0040 
c ----------------------------------------------------------------------------- 
c Material for 1.53% Au with diffusion 
c ----------------------------------------------------------------------------- 
c "Tumor" layer Au 
  m3    1000.04p       -0.1004 
        6000.04p       -0.1408 
        7000.04p       -0.0335 
        8000.04p       -0.6991 
       11000.04p       -0.0010 
       15000.04p       -0.0020 
 109 
       16000.04p       -0.0030 
       17000.04p       -0.0010 
       19000.04p       -0.0039 
       79000.04p       -0.0153        $ 1.53 % mass fraction of gold 
c 
c Tissue with diffused Au at 3.5:1 ratio 
  m4    1000.04p       -0.1016 
        6000.04p       -0.1424 
        7000.04p       -0.0339 
        8000.04p       -0.7067 
       11000.04p       -0.0010 
       15000.04p       -0.0020 
       16000.04p       -0.0030 
       17000.04p       -0.0010 
       19000.04p       -0.0040 
       79000.04p       -0.0044        $ 0.44 % mass fraction of gold 
c 
c Tissue with diffused Au at 8.5:1 ratio 
  m5    1000.04p       -0.1018 
        6000.04p       -0.1427 
        7000.04p       -0.0339 
        8000.04p       -0.7088 
       11000.04p       -0.0010 
       15000.04p       -0.0020 
       16000.04p       -0.0030 
       17000.04p       -0.0010 
       19000.04p       -0.0040 
       79000.04p       -0.0018        $ 0.18 % mass fraction of gold 
c ----------------------------------------------------------------------------- 
c Material for 2.77% Au with diffusion 
c ----------------------------------------------------------------------------- 
c "Tumor" layer Au 
  m6    1000.04p       -0.0992 
        6000.04p       -0.1390 
        7000.04p       -0.0331 
        8000.04p       -0.6902 
       11000.04p       -0.0010 
       15000.04p       -0.0019 
       16000.04p       -0.0029 
       17000.04p       -0.0010 
       19000.04p       -0.0039 
       79000.04p       -0.0277        $ 2.77 % mass fraction of gold 
c 
c Tissue with diffused Au at 3.5:1 ratio 
  m7    1000.04p       -0.1012 
        6000.04p       -0.1419 
        7000.04p       -0.0337 
        8000.04p       -0.7043 
       11000.04p       -0.0010 
       15000.04p       -0.0020 
       16000.04p       -0.0030 
       17000.04p       -0.0010 
       19000.04p       -0.0040 
       79000.04p       -0.0079        $ 0.79 % mass fraction of gold 
c 
c Tissue with diffused Au at 8.5:1 ratio 
  m8    1000.04p       -0.1017 
        6000.04p       -0.1425 
        7000.04p       -0.0339 
        8000.04p       -0.7076 
       11000.04p       -0.0010 
       15000.04p       -0.0020 
       16000.04p       -0.0030 
 110 
       17000.04p       -0.0010 
       19000.04p       -0.0040 
       79000.04p       -0.0033        $ 0.33 % mass fraction of gold 
c ----------------------------------------------------------------------------- 
c Material for 4.00% Au with diffusion 
c ----------------------------------------------------------------------------- 
c "Tumor" layer Au 
  m9    1000.04p       -0.0979 
        6000.04p       -0.1373 
        7000.04p       -0.0326 
        8000.04p       -0.6816 
       11000.04p       -0.0010 
       15000.04p       -0.0019 
       16000.04p       -0.0029 
       17000.04p       -0.0010 
       19000.04p       -0.0038 
       79000.04p       -0.0400        $ 4.00 % mass fraction of gold 
c 
c Tissue with diffused Au at 3.5:1 ratio 
  m10   1000.04p       -0.1008 
        6000.04p       -0.1414 
        7000.04p       -0.0336 
        8000.04p       -0.7018 
       11000.04p       -0.0010 
       15000.04p       -0.0020 
       16000.04p       -0.0030 
 
       17000.04p       -0.0010 
       19000.04p       -0.0040 
       79000.04p       -0.0114        $ 1.14 % mass fraction of gold 
c 
c Tissue with diffused Au at 8.5:1 ratio 
  m11   1000.04p       -0.1015 
        6000.04p       -0.1423 
        7000.04p       -0.0338 
        8000.04p       -0.7067 
       11000.04p       -0.0010 
       15000.04p       -0.0020 
       16000.04p       -0.0030 
       17000.04p       -0.0010 
       19000.04p       -0.0040 
       79000.04p       -0.0047        $ 0.47 % mass fraction of gold 
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APPENDIX C 
Elemental compositions used in simulations 
 
Given below are the relevant tissue compositions used in the MCNP5 simulations given 
in this work.  All data is referenced from Report 46 of the ICRU [13]. 
 
Table C-1 Elemental composition of materials used in simulations (% by mass) 
Organ / Tissue H C N O Na P S Cl K Other 
Blood 10.2 11.0 3.3 74.5 0.1 0.1 0.2 0.3 0.2 0.1 Fe 
Skin 10.0 20.4 4.2 64.5 0.2 0.1 0.2 0.3 0.1 - 
Muscle tissue 10.2 14.3 3.4 71.0 0.1 0.2 0.3 0.1 0.4 - 
Bulk soft tissue 10.5 25.6 2.7 60.2 0.1 0.2 0.3 0.2 0.2 - 
 
Given below are the different concentrations of gold used for each of the models used in 
this work.  No gold concentration was assumed in normal tissue unless indicated below. 
 
Table C-2 Different gold concentrations used in simulations 
  Tumor volume Other 
Preliminary 
model 
Source dependence 0.7 % - 
Depth dependence 0.7 % - 
Concentration dependence 
– Hainfeld values 
0.7 %, 1.2 %, 3.0 % - 
Detailed 
model 
Concentration dependence 
– Chithrani values 
1.53 %, 2.77 %, 4.00 % - 
Penetration (homogeneity) 
dependence 
1.53 % 
a
 
 
 
2.77 % 
a
 
0.44% (3.5:1 ratio) 
b
 
0.18% (8.5:1 ratio) 
b
 
 
0.79% (3.5:1 ratio) 
b
 
0.33% (8.5:1 ratio) 
b
 
Specificity dependence 1.53 % 
0.44% (3.5:1 ratio) 
c
 
0.18% (8.5:1 ratio) 
c
 
 
a. Concentration at tumor periphery; b. Tumor periphery to core ratio; c. Tumor to tissue ratio 
1 % = 10 mg Au per kg of targeted tissue 
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APPENDIX D 
Mass attenuation coefficients 
 
Listed here are the mass attenuation coefficients for gold and tissue separately, followed 
by a comparison of the two over orthovoltage and low megavoltage photon energy levels. 
The tables below list the electron shell energies and Figs. D-1, D-2, and D-3 are plotted 
over the discussed energy range for easy visualization of the physical processes that 
dominate in each energy range.  All attenuation coefficient data given below was 
obtained from [83]. 
 
Table D-1: Absorption edge energy and cross sections for pure gold 
 
Energy (MeV) 
Total attenuation 
cross section (cm2/g) 
Absorption 
edge 
2.21E-03 9.94E+02 M5 
2.29E-03 2.36E+03 M4 
2.74E-03 2.54E+03 M3 
3.15E-03 1.93E+03 M2 
3.43E-03 1.65E+03 M1 
1.19E-02 1.87E+02 L3 
1.37E-02 1.76E+02 L2 
1.50E-02 1.64E+02 L1 
8.07E-02 8.90E+00 K 
 
Table D-2: Absorption edge energy and cross sections for healthy tissue 
Energy (MeV) 
Total attenuation 
cross section (cm2/g) 
Absorption 
edge 
1.07E-03 2.97E+03 K edge for Na 
2.15E-03 4.39E+02 K edge for P 
2.47E-03 2.96E+02 K edge for S 
2.82E-03 2.06E+02 K edge for Cl 
3.61E-03 1.02E+02 K edge for K 
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Figure D-1: Mass attenuation coefficients for gold separated by interaction type 
Figure D-2: Mass attenuation coefficients for tissue separated by interaction type 
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Discussion concerning the difference in attenuation coefficients for gold and 
tissue is included in Chapter 1.  A brief mention was made at the end of Chapter 1 
concerning the difference between the mass attenuation coefficient and the mass-energy 
absorption coefficient.  The equation relating the two is reprinted here with the necessary 
equations for the g factors for the photoelectric effect, Compton scattering, and pair 
production available in [14]. 
 
 

en   1 g tr  (1-6 reprint) 
 
 
 
 
 
 
Figure D-3: Comparing mass attenuation coefficients for healthy tissue and gold 
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While the mass attenuation approximation is sufficient to understand the physical 
significance of the variables included in the model, the inherent error becomes apparent 
at photon energies between 100 keV and 10 MeV as shown in Fig. D-4.  As a result, the 
radiation emitted, and the corresponding energy deposited, due to the secondary charged 
particles travelling through the medium cannot be ignored for microscopically accurate 
simulations.  The work given here assumed macroscopic accuracy and ignored the effects 
of the g correction factor.  Future work will need to be more accurate in order to make 
use of the modified F8 detector tally. 
Figure D-4: Difference in mass attenuation and mass-energy absorption 
coefficients. 
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